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ABSTRACT

The Bioactive Properties of Syringomycin E-Rhamnolipid
Mixtures and Syringopeptins

by

Mekki F. Bensaci, Doctor of Philosophy
Utah State University, 2009

Major Professor: Dr. Jon Y. Takemoto
Department: Biology

The need for new antimicrobial agents has become important in the last decade
due to emerging resistance to a number of conventional antimicrobial agents. New
approaches and sources are needed to generate novel and effective antimicrobials. For
example, synergistic combinations between two or more agents may lead to new
antimicrobial therapies. Furthermore, the increase in health problems caused by the
exposure to agricultural crop pesticides and synthetic fungicides and the emerging
development of organic farming has increased the necessity to develop natural products
than can be used safely in controlling crop diseases.
In this work, I present the first studies on the bioactive properties, particularly
fungicidal activities, of mixtures of SRE and rhamnolipids. The in vitro results clearly
showed strong synergism between SRE and rhamnolipids against phytopathogenic fungi
and yeast. However, no activity was observed against bacteria. The hemolytic activities
and cytotoxicities of SRE and SYRA were dose dependent.
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SRE acts on yeast and plant plasma membranes to cause numerous cellular
effects. The effects are consistent with SRE’s ability to form ion-conducting voltage
sensitive channels in membrane bilayers. In addition, studies with yeast have revealed
that sphingolipids and sterols modulate the fungicidal activity of SRE. Saccharomyces
cerevisiae sphingolipid and sterol biosynthetic mutants were used to investigate the
mechanism of action of SYRA against fungi. These results suggest that similar to SRE,
SYRA antifungal action is promoted by sphingolipids and sterols of the plasma
membrane and involves pore formation.
I further explored the antimicrobial spectrum of syringopeptin SP25A and show that
it specifically inhibits Gram-positive bacteria and yeast.

I also investigated its

mechanism of action against yeast and bacteria. The results revealed the role for Dalanylation of teichoic acids in modulating the susceptibility of B. subtilis to SP25A and
other syringopeptins.

This is consistent with the charged nature of the cyclic peptide

portions of the syringopeptins, and it provides an explanation for SP25A’s higher degree
of specificity for Gram-positive bacteria. In addition and similar to SRE, SP25A
antifungal action is promoted by sphingolipids and sterols of the plasma membrane and
involves pore formation.
Overall, the research shows that SRE and rhamnolipids are synergistically active
against yeast and fungi and that the syringopeptins have antimicrobial activities against
yeast and Gram-positive bacteria. Insights into the mechanisms of action of the SRE and
rhamnolipid mixtures and the syringopeptins and their potential as novel antimicrobial
agents are revealed.
(173 pages).
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CHAPTER 1
INTRODUCTION AND LITERATURE REVIEW

Cyclic Lipodepsipeptides of Pseudomonas syringae pv syringae
The phytopathogenic strains of Pseudomonas syringae pv. syringae produce two
major groups of cyclic lipodepsipeptides: the small cyclic lipodepsinonapeptides and the
larger syringopeptins (2, 11, 83). Individual P. syringae pv. syringae isolates typically
produce one of a variety of forms of the syringopeptins and one form of the smaller
lipodepsinonapeptides (6, 74).
Four

groups

of

small

cyclic

lipodepsinonapeptides

are

well

known:

syringomycins (Fig. 1.1), syringostatins, syringotoxins and pseudomycins (31). They all
contain a long, unbranched-3-hydroxy fatty acid, with a positively charged and a
hydrophilic cyclic ring of nine amino acids at the C terminus (31, 74). These small cyclic
lipodepsipeptides are considered to be antifungal (31). They exhibit fungicidal activity
against various yeast and filamentous fungi such as Candida, Cryptococcus, Geotrichum,
and Aspergillus species (11, 23). Previous studies showed that these compounds tend to
be more active against yeasts than against filamentous fungi (54, 76).

Inhibitory

activities against bacteria are not typically observed for the cyclic lipodepsinonapeptides
(47).

In addition to their antifungal activities, the cyclic lipodepsinonapeptides are

hemolytic and cytotoxic to mammalian cells (22, 76).
The syringopeptins (SPs) are larger and more hydrophobic than the cyclic
lipodepsinonapeptides. The best-studied syringopeptins are SP22 and SP25 (Fig. 1.2)
(4). Structural analyses of these metabolites using 1H and 13C NMR (2) and tandem mass

2
spectrometry (2) revealed that SP22 and SP25 possess 22 and 25 amino acids,
respectively (Fig. 1.2).

The amino acids are predominantly hydrophobic with a

prevalence of valines and alanines. About 70% of the chiral amino acids residues are of
the D configuration, and there are four α,β-unsaturated and two 2,4- diaminobutyric acid
residues (2, 4, 32, 70). An N-terminal amino acid dehydroaminobutyric acid (Dhb) is Nacylated by a 3-hydroxylated fatty acid chain containing ten and twelve carbon atoms
giving homologs designated A and B, respectively, and typically the more abundant and
less abundant forms, respectively. The C-terminal carboxyl group is esterified by the
hydroxyl group of the alloThr residue positioned at the distance of seven residues, thus
forming an eight-membered lactone macrocycle. Recent studies have shown that SPs
have antimicrobial activity against Gram-positive bacteria Bacillus megaterium and
Micrococcus luteus (54). However, the activities against other bacterial species have not
been reported. The SPs are also antifungal but with less potency than the small cyclic
lipodepsipeptides.
Other species of Pseudomonas such as P. syringae pv. atrofaciens (87),
P. fuscovaginae (5), P. tolaasi (66) and P. corrugata (28) also produce cyclic
lipodepsipeptides (CLPs) that have antimicrobial properties. Studies by Vassilev et al.
(87) showed that P. syringae pv. atrofaciens, the causal agent of basal glume of cereals
and grasses, also produces SRE and SP25A.

P. fuscovaginae, the causal agent of

bacterial brown sheath, produces syringotoxin and fuscopeptins (5, 30).

Structure

analysis revealed that the fuscopeptins structure differs slightly from SP22.

The

fuscopeptin lactone ring contains five amino acids rather than eight in the case of SP22.
However, Like SPs, fuscopeptins have a high content of hydrophobic amino acids and
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amphiphilic properties (5). The biological properties of the fuscopeptins more closely
resemble those of the SPs than of the cyclic lipodepsinonapeptides (5, 30).

The

phytopathogenic bacterium from tomato, P. corrugata (69, 28) produces cyclic
lipodepsipeptides known as corpeptin (MW 2121) and cormycin (MW1274). Structural
analysis of corpeptin (CP) and cormycin (CM) revealed that overall these two are
structurally similar to SPs and lipodepsinonapeptides, respectively. The main differences
between CM and small lipodepsipeptides were attributed to the molecular net charge and
the nature of the amino acids occurring at positions 2–6 (69). The CP peptide moiety and
fatty acid moiety show very high homology to those of the SPs (28). Additionally, CP
and CM display antimicrobial activities against bacteria and yeast (28, 69).

The

antimicrobial activities of CP and the SPs are similar. It was shown that CP was more
active against Gram-positive bacteria than against yeast (28). Interestingly, Scaloni et al.
(69) also showed that CM inhibits both bacteria and yeast. The antibacterial observation
was not consistent with the antimicrobial activities of the other small lipodepsipeptides.
CM also exhibited phytotoxic effects and hemolytic activity (69). Finally, Scaloni et al.
(69) have shown that CM forms pores in planar lipid bilayers and its primary target is the
plasma membrane.
Recent studies by De Bruijn et al. (21) using genomic analyses have revealed new
CLPs produced by the bacterium strain P. fluorescens SBW25.

Structure analyses

revealed that the CLPs produced by SBW25 contain 9 amino acids linked to 3hydroxydecanoic acid. The structural features of SBW25 CLP are closely similar to
another CLP produced by P viscosa called viscosin (55). In addition, the bioactivity
studies showed that the SBW25 CLPs play roles in motility, biofilm formation and also
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have antifungal activity against zoospores of Phytophthora infestans (21). This discovery
shows that genome analyses are useful tools that complement structural analyses for
finding new antibiotics produced by microorganisms.

Biosynthesis of Cyclic Lipodepsipeptides
The biosynthesis of the cyclic lipodepsipeptides is a non-ribosomal, templatedirected process. Certain enzymes – but not all - responsible for cyclic lipodepsipeptide
production have been identified (11, 35). The biosynthesis of SRE has been the most
thoroughly studied among the cyclic lipodepsipeptides.
SRE synthesis takes place on a multienzymatic thiotemplate. Analysis of the syrB
and syrC genes of P. syringae pv. syringae indicates that syringomycin is synthesized by
a thiotemplate mechanism (89). The syringomycin (syr) gene cluster contains a DNA
region of approximately 37 kb on the chromosome of P. syringae pv. syringae B301D
(36, 89).

The gene cluster encodes four proteins (SyrB1, SyrB2, SyrC and SyrE)

involved in biosynthesis (36, 89).

The syrE gene encodes a 1,039 kDa synthetase

containing eight amino acid activation modules (36). The syrB gene represents an operon
that expresses two proteins (89). SyrB1 is a 68 kDa protein that carries adenylation and
thiolation domains, and the 35 kDa SyrB2 protein (11).

The syrC gene is located

between the syrB operon and syrE (36). The syrC gene encodes a 48 kDa protein similar
to several proteins containing thioesterase enzyme motifs (86). The syrD gene encodes a
63 kDa protein that is involved in secretion of syringomycin E and is a member of the
ATP Binding Cassette transporter protein family (65).
The regulatory mechanisms for SRE production are complex. The regulation of
syringomycin production by P. syringae pv. syringae is modulated by both nutritional
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factors and plant signal molecules (34). For example, iron exerts a positive regulatory
effect on SRE production, whereas inorganic phosphate represses the production (35). In
addition, plant signal molecules such as arbutin also play a role in SRE synthesis. The
syr gene cluster contains a regulatory gene called syrP that is responsible for the control
of SRE production (91). SyrP is a 40 kDa protein that may function in a phosphorelay
signal transduction pathway (65, 90), therefore, it is believed to be a component of a
kinase cascade that regulates syringomycin production. Another gene, known as syrA ,
identified by Xu and Gross (88), encodes a regulatory protein required for both
syringomycin synthesis and pathogenicity.
Global regulation of SRE production has been well studied (44, 68). The lemA
and gacA genes encode members of a two-component sensory transduction system of
P. syringae pv. syringae that regulates toxigenesis and the ability to cause necrotic
lesions in plants (44). LemA is a transmembrane histidine protein kinase activated by an
extracellular signal that phosphorylates GacA (44, 68). GacA is assumed to function as a
transcriptional activator (68). The LemA-GacA protein pair appears to be at the top of
the regulatory hierarchy controlling SRE production (11). Strains with mutations in
either GacA or LemA do not produce syringomycin E. Kitten et al. identified salA as a
member of the lemA-gacA regulon that can restore SRE production if it is overexpressed
(52). Also, it was reported that the expression of syrB-lacZ was reduced to less than 3%
in a salA mutant (52). The predicted SalA protein sequence exhibits an H-T-H DNAbinding motif with similarity to response regulators (3). It remains to be determined if
SalA binds directly to the promoter region of syrB operon or activates the operon
indirectly through intermediate regulators such as SyrP (52) (11).
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SPs are also synthesized by non-ribosomal mechanisms and multienzymatic
peptide synthetases (73). Mapping and sequence analysis have indicated that the syp
gene cluster is located adjacent to the syr gene cluster (11, 37). Almost the entire syp and
syr gene clusters are located on approximately 145 kb DraI fragment on the chromosome
of P. syringae pv.syringae (73). The syp gene cluster is estimated to encompasss 80 kb
of DNA, and 70 kb of DNA from this region is dedicated to encoding peptide
synthetases. Mutations located in regions encoding peptide synthetase disrupted either
syringomycin or SPs production indicating that these two are synthesized by separate
peptide synthetase systems (73). The syr-syp gene cluster contained genes of phytotoxin
regulation (syrP, salA, syrF,and syrG) and secretion (syrD), in addition to syringomycin
and SP biosynthesis genes (syrE, syrB1, syrC, and sypA) (72). Guenzi et al. (36) showed
that SypA, SyrB, and SyrC exhibit 45.5, 45.6, and 45.9 % identity, respectively to SyrE,
and 42.7, 44.3, and 43.3 % , respectively to SyrB1, both of which are syringomycin
synthetases.

SP is produced under the same conditions as syringomycin.

It was

suggested that the synthesis of SP is activated by the same regulatory system that
regulates syringomycin (11).

Syringomycin E Mechanism of Action
Physiological studies. SRE produced by P. syringae pv. syringae is the best
studied of the small cyclic lipodepsipeptides. Recent studies with SRE have focused on
the antifungal mechanism of action of the small cyclic lipodepsinonapeptides (40). The
amphipathic lipopeptide structure of SRE promotes its interaction with the plasma
membrane as the first site of action (11). Previous work by Zhang and Takemoto (92) on
Rhodotorula pilimanae showed that SRE causes an increase in tetraphenylphosphonium
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uptake indicating an increase in membrane potential (92). This results in a variety of
effects such as K+ effluxes and H+ influx which eventually result in cell death (93). In
plants, SRE induced stomata closing in Xanthium strumarium and Vicia faba by causing
K+ efflux (59). A reversal effect was observed when fusicoccin was applied. This result
leads to an argument that SRE does not permanently disrupt the plasma membrane (59).
Other studies show that SRE collapses the pH gradient across the plasma membrane by
inducing K+ efflux and H+ influx (11, 67, 92). Moreover, it was also shown that H+ATPase activities of R. pilimanae and red beet storage tissue were stimulated by SRE
(13).

However, no stimulation was observed when purified enzyme was used; this

suggests that SRE’s stimulation effect was not directly on the enzyme and that other
components are involved. In addition to K+ and H+ exchange, SRE also stimulates Ca2+
influx (84, 85). Studies with syringomycin E-treated red beet storage tissue have shown
an overall increase in Ca2+ uptake (84, 85). The influx of Ca2+ was followed by a cascade
of events associated with cellular signaling in plants (84) such as the induction of kinasemediated phosphorylation of membrane proteins (H+-ATPase) (13) and the incorporation
of 1,3-B-callose into plant cell walls (11, 51).
Bilayer studies. In recent years more studies were done to characterize SRE
channel formation and properties using artificial lipid membranes. Studies by Hutchison
and Gross (45) and Feigin et al. (29) revealed that SRE forms voltage-dependent channels
in artificial planar bilayer membranes.

These studies revealed that SRE forms non

specific pores which are permeable to both monovalent and divalent cations. It was
shown that at least six SRE molecules are required for channel formation and the pore
radius was estimated to be 1 nm (29) (18) (46). In addition, Ostroumova et al. (62)
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showed that SRE channels are larger at the trans side with radii of 0.5-0.9 nm versus
0.25-0.35 at the cis side, concluding that the SRE channel is asymmetrical. Additional
studies showed that SRE forms two types of channels, “small” and “large” differing 6 to
7 times in their conductance (49, 71). The SRE channels cluster transiently and exhibit
synchronous channel opening and closing resulting in the wide range of conductances
(49). In addition, these channels display temperature-dependent pore inactivation (58,
71, 81) .

The Roles of Yeast Sphingolipids and Sterols
In yeast, sphingolipids and sterols play important roles in the action of SRE.
Sphingolipids are major components of the eukaryotic plasma membrane, and they
represent about 8 % of its total mass (42, 63). The sphingolipids are composed of a long
chain base with an amide-linked fatty acid at the C-2 position and a polar constituent at
the C-1 position. Sphingolipids are ubiquitous in eukaryotes, and they play roles in many
cellular functions such as protein glycophosphatidylinositol (GPI) anchoring, heat stress
responses, and modulation of membrane enzyme activities (27, 64).
The biosynthesis of S. cervisiae sphingolipids has been well elucidated, and the
major functional genes for sphingolipid biosynthesis have been identified
(Fig. 1.3) (26). The first step of sphingolipid biosynthesis begins with condensation of
palmitoyl-CoA and serine to form 3-ketodihydrosphingosine (14). The condensation
reaction is catalyzed by a multi-subunit membrane enzyme serine palmitoyl transferase.
In S. cerevisiae this enzyme is encoded by LCB1 and LCB2 (9, 15, 60). The next step of
sphingolipid biosynthesis involves the reduction of 3-ketodihydrosphingosine to
dihydrosphingosine by the NADPH-dependent reductase TSC10 (80). In yeast this is
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followed by conversion of dihydrosphingosine into phytosphingosine by hydroxylation at
the C4 position of the sphingoid base by the SYR2/SUR2 gene product (17, 27, 33, 38). A
special feature of sphingolipids is its very long fatty acyl side chain that contains 24 to 26
carbons atoms. The synthesis of these long chains is done by the ELO2 and ELO3 that
convert C16 and C18 fatty acids to C20 and C26 sphingolipid molecules (Fig. 1.3).
In addition, the FAH1 is responsible for α-hydroxylation of the amide linked very long
chain fatty acids.
Three

main

forms

of

sphingolipids

are

formed

in

S.

cerevisiae

inositolphosphorylceramide (IPC) (78), mannosyl-inositolphosphorylceramide (MIPC),
and mannosyl-diinositolphosphorylceramide (M(IP)2C) (75) (Fig. 1.3). The formation of
these three lipids requires successive additions of phosphorylinositol, mannose and a
second phosphorylinositol to ceramide. First, the transfer of phosphorylinositol from
phosphatidylinositol to ceramide is catalyzed by IPC synthase encoded by AUR1 (60).
Then, a mannose group is added to IPC to form mannosylinositolphosphoceramide
(MIPC). This step in yeast requires the genes CSG1 and CSG2 (9) (10). Finally, the last
step in sphingolipids biosynthesis is the transfer of phosphorylinositol to M(IP)2C. This
step is catalyzed by M(IP)2C synthase, the encoded protein of SYR4/IPT1 (27, 56).
Findings with S. cerevisiae mutants resistant to SRE have shown that structural
features of sphingolipids and sterols are involved in SRE’s mechanism of action
(Fig. 1.4). For instance, one of the genes that promotes SRE action is SYR1/ERG3, which
encodes the sterol C5,6 desaturase for the biosynthesis of ergosterol, the primary sterol in
yeast plasma membrane (82). The expression of specific sphingolipid biosynthetic genes
SYR2, FAH1, ELO2, ELO3 CSG1, CSG2 and IPT1 also promote SRE action. A mutation
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in any one of the genes causes no cell lethality, but each renders resistance to the killing
effects of SRE (40, 79). In addition, the work of Kaulin et al. (50) revealed that the C4OH sphingoid base is important for SRE channel forming ability and a mutation in the
C4-hydroxylase gene SYR2 causes a reduction in the number of pores formed by SRE.

Mechanism of Action of Syringopeptins
Despite the structural differences between SRE and the SPs, both elicit similar
physiological and membrane biophysical responses. Several studies have shown that the
SPs are capable of forming ion conducting membrane pores (19, 45). The amphipathic
nature of the SPs facilitates their insertion into lipid bilayers causing channel formation
and disruption of the membrane. In plant systems, the SPs have been shown to cause
electrolyte leakage in leaf tissues, which leads to the development of necrotic symptoms
(47). In addition, Di Giorgio et al. (25) have shown that the SPs can alter the distribution
of H+ across the plasma membrane of maize cells and promote stomatal closure in
Xanthium strumarium leaves. The SPs also induce lysis and generate a rapid influx of
45

Ca2+ across the plasma membrane of tobacco protoplasts (45). In yeast, SP action is

promoted by sphingolipids and sterols of the plasma membrane (Bensaci et al., 2008
submitted and Chapter 4, this dissertation). Finally, the SPs interact with the bacterial
cell surface teichoic acids (12) but the mechanism of interaction with bacterial
membranes is still unknown.
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Biosurfactants
Diversity, Properties, and Roles
Biosurfactants are a structurally diverse group of surface active molecules
synthesized by a variety of microorganisms (bacteria, yeast and fungi) (24, 77).
Biosurfactants are categorized mainly by their chemical composition and their microbial
origin (7).

There are six types of biosurfactants: lipopolysaccharides, glycolipids,

lipopeptides-lipoproteins, phospholipids, and hydroxylated and cross-linked fatty acids
(mycolic acids) (7, 24).

The biosurfactants are amphiphatic molecules.

As a

consequence, these molecules have the ability to reduce surface and interfacial tensions
in both aqueous solutions and hydrocarbon mixtures (8). In addition, biosurfactants are
biodegradable, low in toxicity, ecologically acceptable, and can be produced from
renewable substrates (57). In nature the functions of biosurfactants are not clear (77)
However, it has been proposed that biosurfactants play a variety of roles that include: a)
enhancement of bioavailability and biodegradation of slightly soluble organic carbon
sources such as petroleum hydrocarbons (77) (b) attachment and detachment of bacterial
cells to surfaces (77), and defense strategies against other microbes (c) (77).
Biosurfactants are also used in cosmetics, health, pharmaceuticals, agriculture, and the
food industry (57).

Rhamnolipids
Among the glycolipid biosurfactants, rhamnolipids are the most studied.
Rhamnolipids are produced by certain Pseudomonads and were first described in 1949 by
Jarvis et al. (48). Their biosyntheses have been well studied by Hauser and Karnovsky
and Burger et al. (16, 41) . Rhamnolipids are secreted by Pseudomonas aeruginosa
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during the stationary phase of growth under limiting conditions of nitrogen and iron (41,
61). The synthesis of rhamnolipids proceeds by sequential glycosyl transfer reactions,
each catalyzed by specific rhamnosyltransferases with TDP-rhamnose acting as a
rhamnosyl donor and
3-hydroxydecanoyl-3-hydroxydecanoate serving as the acceptor (53, 61).

Structural

analysis revealed that glycolipid biosurfactants are formed by the linking of rhamnose to
fatty acids composed of saturated or unsaturated alkyl chains with lengths between C8
and C12 (Fig. 1.5) (39). Their molecular weights range from 504 to 650 (78, 94).

Antimicrobial Activities of Rhamnolipids
Rhamnolipids possess antimicrobial activities (39).

They are active against

zoosporic plant pathogens such as Phythium and Phytophthora species (77).
Rhamnolipids are also active against fungal species such as Fusarium solani and
Penicillium funiculosum (1, 39). Haba et al. (39) have shown that rhamnolipids also have
antibacterial activities against certain Gram-negative and Gram-positive bacteria. Among
the Gram-negative and Gram-positive bacteria tested, Klebsiella pneumoniae,
Entrobacter aerogenes, Bacillus subtilis and Micrococcus luteus were the most sensitive
to rhamnolipids (1, 39). However, no activity against yeast was observed (1, 39). The
mechanism of action of rhamnolipids against fungi is still unknown.

However,

Stanghellini et al. (77) suggested that the rhamnolipids inhibit zoosporic fungi by
disrupting the zoospore plasma membrane.
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Crop Fungicides
Fungicides are extensively used in agriculture for a number of purposes including
protection of crops, seedlings, and storage. About 150 different fungicidal compounds
are currently used with a global market value of about 6 billion U.S. dollars accounting
for almost 20% of the agrochemicals market (43).
Fungicides can be classified in two groups based on their source: synthetic
organic chemicals and naturally-derived fungicides (20). Organomercurials were the first
synthetic organic chemicals used as agrofungicides in the early twentieth century (20).
Later, varieties of organic fungicides were introduced such as: ferbam, ziram, and
dinocap. These compounds are known to be multisite inhibitors. They disturb fungal
physiology by interacting with functional groups of enzymes and other key constituents
of fungal cells (20). Their non-selective action sometimes cause undesirable effects in
plants, mammals, and beneficial organisms (20). Therefore, in the early 1960s, new
measures and regulations were adopted to limit the use of these fungicides and to
promote the search for novel fungicides with specific target sites (20). The search
resulted in the discovery of specific-site fungicides such as the benzimidazoles, Narylcarbamates,

sterols

and

melanin

biosynthesis

inhibitors,

phenylpyrroles,

dicarboximides, and other fungicides such as aromatic hydrocarbons (20). However, due
to the increase in resistance, side effects in mammals and wildlife with extensive use, and
the low biodegradability of these compounds (20), a new effort was promoted to screen
microbial products in order to discover new natural compounds that are highly
biodegradable and low in toxicity. The search led to the first discovery by Takeuchi et al.
in 1958 of blasticidin A (20).

This fungicide is produced by Streptomyces
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griseochromogenes.

It was used for the control of rice blast disease caused by

Pyricularia oryzae. Following this discovery more fungicides of microbial origin such as
kasugamycin, polyoxins, validamycin A, and mildiomycin were discovered and used in
agriculture (20). Prior to 1970, most of the used fungicides were multisite inhibitors.
Resistance to these compounds is rare. However, with the use of site specific fungicides
the rate of resistance increased dramatically and the time between commercial
introduction and the emergence of resistance was much shorter than with the multisite
fungicides. A good example of resistance is the outbreak of benzimidazole resistance of
Cercopsora beticola in sugar beet and the loss of matalaxyl control of Phytophthora
infestans (43). Fungicide resistance can have significant impacts on agriculture and crop
protection that include economic loss. Awareness of these problems led researchers to
define the factors which influenced the spread of resistance and to seek strategies to
combat it (43). However, resistance is not the only factor to limit the use of particular
fungicides. Selectivity and the distinct spectra of activity are a concern because most
specific site fungicides have limited use against certain important plant pathogens (20).
These problems raise the call for new and effective fungicides with broad spectra and no
resistance.

Justification and objectives for the present research
The need for novel antimicrobial agents has become important in the last decade
due to emerging resistance to a number of conventional antimicrobial agents. New
approaches and sources are needed to generate novel and effective antimicrobials. For
example, synergistic combinations between two or more agents may lead to new
antimicrobial therapies. Furthermore, the increase in health problems caused by the
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exposure to agricultural crop pesticides and synthetic fungicides and the emerging
development of organic farming has increased the necessity to develop natural products
than can be used safely in controlling crop diseases.
The overall aim of the research is to investigate the bioactive and synergistic
properties

(particularly

fungicidal

activities)

of

mixtures

of

the

cyclic

lipodepsinonapeptide SRE and rhamnolipids. Being natural products, there is interest in
the commercial applications of both compounds as fungicides. Both are physically and
chemically similar with the ability to be extracted and processed using similar procedures
from cultures of fluorescent pseudomonads.

Rhamnolipids are now commercially

available, and industrial production of SRE is under development. If synergistic, the
mixtures of the two could have major applications in agricultural crop disease control as
well as other important applications involving control of fungal growth. In the present
research, the bioactive properties of SRE, rhamnolipids, and combination mixtures of the
two were investigated.
The objectives of the research were to study:
1) the parameters of SRE-rhamnolipid mixtures (SYRAs) that give optimal
antimicrobial activities against yeasts, fungi and bacteria,
2) the spectrum of fungal species that are inhibited by SYRAs,
3) the fungicidal mechanism of action of SYRAs,
4) the toxicities of SYRAs on mammalian cell lines, red blood cells, and
honeybees.
5) the possibility of other pseudomonad cyclic lipodepsipeptides having
synergistic antimicrobial activities when combined with rhamnolipids.
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FIG. 1.1. Structure of the cyclic lipodepsinonapeptide syringomycin E. Dab:2,4
diaminobutyric acid; Dhb:dehydroaminobutanoic acid; Asp(OH): β-OH aspartic acid;
Thr(Cl): 4-chlorothreonine.

FIG. 1.2. Structure of syringopeptin. R = CH3- (CH2) n-CH (OH)-CH2CO, SP22A (n=6),
SP25A(n=6)Abbreviation Dab=1,4-diaminobutyricacid; Dhb=2,3 dehydroaminobutyric acid; all
other amino acids are identified by standard three letter biochemical notation.
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FIG. 1.4. The S. cerevisiae sphingolipid M(IP)2C. The enzymes that modify precursors
of M(IP)2C during its biosynthesis are shown and the structural modification indicated
.
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FIG. 1. 5. Chemical structures of rhamnolipids produced by Pseudomonas aeruginosa
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CHAPTER 2
THE BIOACTIVE PROPERTIES OF SRE AND
RHAMNOLIPID MIXTURES

Introduction

The need for new antifungals and fungicidal biocontrol agents is growing due to
the narrowing spectra of fungal targets and increasing resistance to existing antifungals
such as amphotericin B and the azoles (30, 31).

One approach to develop novel

antifungals is to combine known antifungal compounds. Such combinations may have
improved bioactivities and expanded target spectra due to the synergy between the
compounds. Moreover, lower effective doses of the combination components may have
less toxicity.
The plant bacterium Pseudomonas syringae pv. syringae produces an array of
antimicrobial peptides known as the small cyclic lipodepsipeptides such as syringomycin,
and the large cyclic lipodepsipeptides known as the syringopeptins (3, 38). The small
cyclic lipodepsipeptides contain an unbranched-3-hydroxy fatty acid with a positively
charged cyclic ring of nine amino acids at the C terminus (14, 32). Their molecular
weights range from 1000 to 1300 (14, 32). The best studied is SRE. Previous studies
showed that SRE has inhibitory activity against fungi and yeast such as Botrytis cinerea,
Geotrichum candidum and Rhodotorula pilimanae (21, 38). It tends to be more active
against yeasts than against filamentous fungi (21). Recent studies have focused on the
antifungal mechanism of action of the small cyclic lipodepsinonapeptide SRE (16) was
shown to form channels in phospholipid bilayers, and it is speculated that a similar
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mechanism occurs in the target fungal membrane (7). Channel formation may cause the
influx of ions such as K+ and Ca2+ (38).
Many strains of Pseudomonas aerginosa produce several homologs of the
biosurfactant known as rhamnolipid (1, 15). Rhamnolipids were first described in 1949
by Jarvis and Johnson (20) and their biosyntheses was well studied by Hauser and
Karnovsky (17). Rhamnolipids are glycolipids secreted at the stationary phase of growth
under limiting conditions of nitrogen and iron (17, 28). Structure analysis revealed that
these compounds are formed by rhamnose linkage to fatty acids of saturated or
unsaturated alkyl chain between C8 and C12 (15). Their molecular weights range from
504 to 650 (37, 41). The antimicrobial activities of rhamnolipids are well studied. They
are active against zoosporic plant pathogens such as Phythium and Phytophthora species
(35). Rhamnolipids are also active against fungal strains such as Fusarium solani and
Penicillium funiculosum (1, 15).

Moreover, Haba et al. (1, 15) have shown that

rhamnolipids also have antibacterial activities against certain gram-negative and grampositive bacteria.

Among the gram-negative and Gram-positive bacteria tested,

Klebsiella pneumoniae, Enterobacter aerogenes, Bacillus subtilis and Micrococcus luteus
were the most sensitive to rhamnolipids (15). However no activity against yeast was
observed (1, 15).
The main objective of this study was to examine the in vitro interaction of SRE
and RL against bacteria, yeast, and filamentous fungi. I investigated the antimicrobial
properties and cytotoxicity of syringomycin E (SRE), rhamnolipids (RLZonix) and the
mixture SYRA (3:1 mixture of RLZonix and SRE).

Synergistic antifungal activities

between SRE and RLZonix in the mixtures (SYRAs) were observed. The SRE minimal
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inhibitory concentrations (MICs) were lowered when combined with RLZonix. However,
no activity was observed against bacteria. In vitro cytotoxicity and erythrocyte lysis were
also investigated. The hemolytic activity and cytotoxicity of SRE, RLZonix and SYRA
were dose dependent. However, the concentrations of SRE and SYRA that caused
hemolysis and cytotoxicity were 3 to 5 times higher than the MICs. In addition, the
honeybees toxicity effect of SRE, RLZonix, and SYRA was also studied. The use of most
pesticides in agriculture has often negative effects against bee populations and
ecosystems. The ecological and agricultural importance of bees requires the use of safe
and less toxic fungicides. The results showed no toxicity at concentrations higher than
the MICs.

Materials and Methods

SRE and Rhamnolipids
SRE was purified from P.syringae pv.syringae strain B301D by the method of
Bidwai et al. (4). P.syringae pv.syringae strain B301D was grown in non-commercial
potato dextrose casamino acids medium in 4 or 8-liter cultures as described by Zhang
et al. (40). The SRE was extracted from cultures using acidified acetone and purified
using the chromatographic methods described by Bidwai et al. (4). HPLC column
fractions were tested for bioactivity by applying 10 µl aliquots on a fresh lawn of R.
pilimanae on potato-dextrose agar plates, incubation at 28oC, and observing cleared
growth inhibition areas (40).
The rhamnolipids (RLZonix) was obtained from Jeneil Biotech, Inc. Zonix contains
8.5 % solution of rhamnolipids in water. Two forms of rhamnolipids are in zonix ,
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R1

(C26H48O9)

has

the

molecular

formula

of

α-L-rhamnopyranosyl-β-

hydroxydecanoyl-β-hydroxydecanoate,R2(C32H58O13),2-O-α-L-rhamnopyranosylα-Lrhamnopyranosyl- β hydroxydecanoate.
Organism and Media
The following organisms were obtained from the microbial culture collection of
the Department of Biology, Utah State University: R. pilimanae ATCC9449, Candida
albicans ATCC10231, Aspergillus flavus, Aspergillus niger, Rhizopus stonifer, Fusarium
oxysporum, Rhizoctonia solani, Botrytis cinerea, Cladosporium cladosporioides,
Penicillium oxalicum, Penicillium sp.

All fungi were cultivated in potato dextrose

medium (Difco) (PDA) at 28 to 30°C. Saccharomyces cerevisiae W303C, S. cerevisiae
BY4741 and S. cerevisiae 8A-1B were obtained from Dr. Takemoto’s laboratory
collection. S. cerevisiae strains were grown on YPD at 28°C. S. aureus ATCC653, B.
subtilis ATCC1965, E. coli ATCC25922, Proteus vulgaris ATCC13315. The bacteria
strains were grown at 37°C for 24 h on Luria-Bertani medium except S. aureus was
grown on Mueller-Hinton medium.

Antifungal Susceptibility
Agar disk diffusion method. The disk diffusion assay was done according to
National Committee for Clinical Laboratory Standards (NCCLS) protocols for antifungal
testing with modification (26) (25). Fungal isolates were subcultured on PDA plates and
incubated for 3 to 5 days at 35°C. The fungal plates were covered with 5 mL of distilled
sterile water. Then, the fungal spores were harvested and suspended in sterile water. The
suspension was adjusted to 106 spores/ml (36). A 100 µl of the suspension was
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transferred and spread uniformly onto solid agar of the appropriate growth medium using
cotton swabs (36).
To test the antifungal activity of SRE in combination with RLZonix, 10 µl of SRE
(1 mg/ml) was applied on disk and placed on plates containing different concentrations of
RLZonix (22). Another test was done by applying SRE and RLZonix to a different disk. The
distance between the disks was equal to the sum of radii of zones of inhibition of the
drugs applied alone. The plates were incubated for 24 to 72 h at 35°C (5) and the zone of
inhibition was measured.

To examine the effect of varying the SRE and RLZonix

concentrations in SYRA, 4 mm diameter sterilized paper disks were deposited on the
surface and 10 µl of different ratio of SRE and RLZonix mixtures were applied.
Tested bacteria were grown in LB broth for 24 h and transferred onto solid agar
medium of the appropriate growth medium. The cultures were spread over the surface as
a thin film (39). Four mm diameter sterilized paper disk was deposited on the surface
and 10 µl of SRE, RLZonix and SYRA were applied. The plates were incubated for 24 h at
37°C and the zone of inhibition was measured.
Hyphal extension assay. The hyphal extension essay was done as described by
Dash et al. (9) with modification. A 100 µl of 1 ×106 spores/ml suspension was paper
strip in a middle of the Petri dish and incubated for 48 h until the appearance of the
growing hyphae. Sterile filter disks (4mm diameter) were deposited in the front of the
growing hyphea and 10 µl of tested solutions were applied to each disk. The plates were
further incubated at room temperature and pictures of the plate were taken at the
designated time.
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Spore suspension assay.

The spore suspension assay was performed as

described by Mauch et al. (23).

The fungal spores were harvested as described

previously.

The spore suspension was adjusted to 1× 106 spores/ml.

The freshly

prepared suspension was spread on a Petri dish plate and incubated for 20 to 24 h at room
temperature. After this period, four mm paper disks were deposited and 10 µl of the test
solutions were applied to the disks. The plates were further incubated and the zones of
inhibitions were measured after 48 h.
Microbroth dilution method. The MICs were determined by the microbroth
dilution assay according to method outlined by the NCCLS with modification (25, 26).
The inocula suspensions were prepared as described previously (5). Fungal isolates were
subcultured on PDA plate and incubated for 3 to 5 days at 35°C. The inoculums
suspensions were prepared from fresh cultures. The fungal plates were covered with 5 ml
of distilled sterile water. Then, the fungal spores were harvested and suspended in sterile
water. After harvesting the spores, the conidia suspensions were diluted with RPMI
medium (RPMI 1640 with L-glutamine buffered to pH 7 with 0.165 M
morpholinepropanesulfonic acids (MOPS) and supplemented with 2% glucose) (18, 25,
29) (HyClone Laboratories) and adjusted to a final concentration of 1 ×105 spores/ml
using cell counting hemocytometer. A 50 µl of the conidia suspensions were added to
each well of 96-well polystyrene microtiter plates (Fisher Scientific catalog no. 21-377203) to achieve a 1x 104 concentration with conidia/ml. Aliquots (50 µl) of twofold serial
dilutions of SRE and RL were added to each well (100 µl total volume). The plates were
incubated for 24 to 72 h at 35°C. The MIC was defined as the lowest concentration that
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completely inhibited the growth. The tests were carried out in three replicates to confirm
the MIC value.
For yeast, cells were grown to a final concentration of 108 CFU/ml and suspended
at a final concentration of 5 x105 CFU/ml. Cell suspensions (25 ml) were added to 25-ml
aliquots of two fold serial dilutions of SRE and RLZonix, and appropriate broth media (27)
were dispensed (100 µl total volume) in wells of 96-well polystyrene microtiter plates
(Fisher Scientific catalog no. 21-377-203). The plates were incubated for 24 h at 28°C.
The colony-forming unit (CFU) experiment was performed under the same
experimental conditions as described for the microbroth dilution.

In brief, starting

inoculum of 1-4 x 105 CFU/ml of C. albicans ATCC10231 were treated with different
concentrations of SRE and SYRA. The CFU were counted by subculturing 100 µl of
serial dilution of each well on PDA. The experiment was performed in three triplicates,
and the results were reported as mean values.
Checkerboard microtiter plate testing. To test the antifungal combinations of
SRE and RLZonix, a checkerboard microtiter assay was done according to the
recommendations of the NCCLS for in vitro susceptibility testing (26). The testing was
done in RPMI 1640 with L-glutamine buffered to pH 7 with 0.165 M of MOPS
supplemented with 2% glucose (12).

A 96-well plate was used to determine the

fractional inhibitory concentration (FICs). Serial twofold dilutions of SRE and RLZonix
was prepared separately. Then, 25µl of different concentrations of SRE was added in a
vertical orientation and 25 µl of different concentrations of RLZonix was added in
horizontal orientation (33). The conidia and yeast cell suspensions were prepared as
described previously (36) and 50 µl of the suspensions were added to each well. The
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final volume of the well contains 50 µl of the drugs and 50 µl of the tested culture. The
plates were incubated for 24 to 72 h at 35°C. The fractional inhibitory concentrations
(FICs) of each drug was defined as the MIC of the combination of SRE and RLZonix
divided by the MIC of the drug alone (12) (33). Then, the FIC index was calculated by
adding up the FICs for each of the drugs (33). The interaction was defined as synergistic
if the FIC index was <1.0, additive if the FIC index was 1.0, and antagonistic if the FIC
index was >2.0 (12, 22).
Time-kill curves. The time-kill curve assay was done according to methods
described by Marchetti et al. (22) with modification. An inoculum of 5 x105 CFU/ml of
C. albicans ATCC10231 was used under the same experimental conditions as described
for the microbroth dilution (27). The effects on viability of SRE (1.97µg/ml) and SYRA
(0.97 SRE + RLzonix 2.92 µg /ml) after 3, 6, 9, 12, and 24 h of incubation were examined.
A synergy effect is defined as ≥2 log10 decrease in CFU per milliliter compared to the
most active ingredient (6, 24).

Toxicity Assays
Hemolysis assay. Hemolytic activity was determined by the method described by
Dartois et al. (8) and Sorensen et al. (34) with modification. Sheep erythrocytes were
used to test hemolytic activity of SRE, RLZonix, and SYRA. Sheep red blood cells (RBC)
were obtained by centrifuging whole blood at 1,000 × g, washed four times with PBS,
and resuspended in 10 ml of PBS to a final concentration of 5% of RBC (8). The RBC
suspension (80 µl) was added to each well containing different concentrations of SRE or
RLZonix or SYRA (20 µl). The plate was incubated at 37°C for 60 min. Deionized water
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and triton X-100 1% (w/v) were used as positive controls. The percent of hemolysis was
calculated using the following equation:
% hemolysis= (absorbance of sample) – (absorbance of blank) ×100/ (absorbance of
positive control). Fifty percent hemolysis (HD50) values were calculated as the sample
concentrations required to lyse 50 % of the RBC (8).
In vitro Cytotoxicity. The cytotoxicity assay against mammalian cells was determined
by the method described by Dartois et al. (8). Cell viability was determined using MTS
(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2Htetrazolium, inner salt; MTS) and the electron coupling reagent, phenazine methosulfate
(PMS). This assay is based on the ability of the cells to convert a soluble tetrazolium salt
to formazan product. The cell lines for the cytotoxicity tests were obtained from the Utah
State University collection. The NIH-3T3 9 (mouse fibroblast), HEK293 and HeLa cells
(American Type Culture Collection, Manassas, VA) were propagated in culture medium
containing 90% (v/v) Dulbecco’s modified Eagle’s medium (D-MEM) (Invitrogen,
Carlsbad, CA), 10 % defined fetal bovine serum (Hyclone Laboratories,Logan, UT).
MDA-MB-435 cells were cultured in a 1:1 mixture of DMEM and Ham’s F12 medium
supplemented with 5% (v/v) fetal bovine serum (Hyclone Laboratories, Logan, UT), 1%
non-essential amino acids, and 1mM sodium pyruvate. Cells were cultured in Corning
tissue culture flasks at 37°C with 5 % CO2. The confluent cells were treated with trypsinEDTA and diluted in serum free media. The cells were transferred into 96-well plates at
a density of 2×105 cells per well and 20 µl of MTS reagent was added to each well
containing 100 µl of cells in culture medium. The cells were incubated in a humidified 5
% CO2 incubator at 37°C for 3 h (8). The plates were read with a microplate reader at
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490 nm. Percent cytotoxicity was calculated as: (control value − test value) × 100/control
value. Lethal concentrations that caused 50% mortality were calculated using Origin 7.0
(OriginLabCorporation, One Round House Plaza, Northampton, MA 01060).
Honeybee toxicity. The test was performed according to methods published by
the U.S. Environmental Protection Agency (EPA) Office of Prevention, Pesticides, and
Toxic Substances (OPPTS) with modification (13). As recommended by the OPPTS,
Apis mellifera species were used. Worker honeybees were captured at the entrance of a
single healthy hive the day of use. The bees were then brought to the laboratory and kept
in a small cage at room temperature. Prior to use, all bees in each cage were anesthetized
with CO2 and transferred to three individual cups to have a total of 10 bees in each cup.
Two tests were performed to test the toxicities of SRE, RLZonix and SYRA. The first test
was done by feeding the bees with 200 µl of different concentrations of SRE, RLZonix and
SYRA (Table.2.4). For the second test, the bees in each cup were anesthetized again
with CO2 and different concentrations of SRE, RLZonix and SYRA were applied in 1 µl
drops to the ventral side of the thorax of each bee. After treatments, the bees were fed
with 3 ml of sucrose solution (50 % volume of sucrose and 50 % volume of water). The
cups were kept at 28°C incubator for 48 h and checked every 4 h. The ratio of living to
dead bees was recorded. The treatments with each concentration were replicated three
times.
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Results

Antifungal Activities
The combination of SRE with RLZonix was tested by an agar disk diffusion assay
in which R. pilimanae was plated onto PDA and PDA with RLZonix (RL-PDA). Different
concentrations of SRE were applied on disks and deposited on RL-PDA and PDA.
The results showed that the zones of inhibition of SRE in RL-PDB were slightly larger
compared to the agar with no RLZonix (Fig. 2.2). This indicates some degree of a positive
interaction between SRE and RLZonix. However, due to the lower concentrations of SRE
the zone of inhibition did not increase noticeably compare to the control.

In the

experiments where SRE and RLZonix were applied to a different disk, no change was
observed in SRE zone of inhibition (data not shown).
In this experiment SRE and RLZonix were mixed at different ratios prior to use.
SRE, RLZonix and SYRA were tested against yeast, fungi and bacteria. SRE and SYRA
showed antifungal activities against all tested fungi and yeast. However, no activity was
observed with RLZonix except against R.pilimanae. A strong synergy between SRE and
RLZonix was observed (Fig. 2.1.). The SYRA activity was much stronger than SRE when
against tested yeast and fungi. For example, against C. albicans, the zones of inhibition
were 20 and 40 mm for SRE and SYRA, respectively (Fig. 2.1, Table 2.1). In addition,
the concentration of SRE in SYRA (0.6mg/ml SRE) applied to the disks to give these
zones of inhibition was 4-fold less than for SRE alone (2.4mg/ml). It is important to note
that the highest zones of inhibition against yeast and fungi were obtained when SRE and
RLZonix were mixed at a ratio of 1:3 (as in SYRA). No activities were observed against
tested bacteria.
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To further investigate the antifungal activity of SRE, RLZonix and SYRA, I tested
their activity against P. oxalicum, R. stonifer, A. flavus, and A. niger both hyphal growth
and germinated spores. In both experiments, SRE and SYRA were inhibitory against
germinated spores and hyphal extension of all tested species (Fig. 2.3 and Fig. 2.4).
However, no activity was observed with RLZonix. The zones of inhibition were from 15 to
20 mm against germinated spores.

However, the activity of SRE and SYRA were

stronger when applied directly after inoculation of the plates (zones of inhibition were
from 25 to 30mm). SRE and SYRA inhibited the hyphal growth as it was demonstrated
by the crescent zone due to the retarded mycelia growth (Fig. 2.4).
To quantify the antifungal activity of SRE, RLZonix and SYRA, the microbroth
dilution and the checkerboard methods were used. SRE inhibited tested fungi and yeast
with MIC’s that ranged from 1.95 to 7.8 µg per ml (Table. 2.1). RLZonix did not show
activity against the tested organisms except R. pilimanae with an MIC of 93.75 µg per
ml. However, no antibacterial activity was observed with SRE and RLZonix.
The SYRA‘s MICs ranged from 0.5 to 3.9 µg /ml (Table 2.1). Based on the data
obtained from the checkerboard assay, the FICs indices of SRE plus RLZonix were ranging
from 0.25 to 0.5 (FIC<1) indicating synergism between these two compounds.

In

addition, SRE and SYRA showed significant reduction in the viable counts against
C.albicans (Fig. 2.5). However, SYRA was more fungicidal than SRE alone.

Time Kill Assay
The synergisms observed between SRE and RLZonix in the checkerboard microtiter
assay were confirmed in time-kill curves experiments. Fig. 2.6. shows time-kill results
for SRE and SYRA. SYRA was more active than SRE alone and displayed much more
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rapid killing against C.albicans. The decreases in CFU with SYRA comply with a
synergistic relationship between SRE and RLZonix .

In vitro Toxicity Studies
Hemolysis assay. SRE, RLZonix and SYRA were found to be hemolytic and
displayed dose dependent hemolytic activity against sheep RBCs (Fig. 2.5). RLZonix was
the least hemolytic among the three.
Cytotoxicity studies. The cytotoxicity effects of SRE, RLZonix and SYRA on
mammalian cell lines are shown in Fig. 2.6. SRE, RLZonix and SYRA displayed a dose
dependent cytotoxicityagainst NIH-3T3 (mouse fibroblast), HEK293, MDA-MB-435,
and HeLa cells (Fig.2.6.). However, the concentrations showing toxic effects on the cell
lines were higher than those needed for hemolytic activity. Interestingly, SRE, RLZonix,
and SYRA displayed more toxicity against the MDA-MB-435 cell line. The MDA-MB435 LC50 for SRE, RLZonix and SYRA were almost three times lower comparing to the
LC50 of NIH-3T3 (mouse fibroblast), HEK293, and HeLa cells (Table 2.3).
Honeybee toxicity. The honeybee toxicity studies of SRE, RLZonix and SYRA
were examined against Apis mellifera. The presented results were from three separate
experiments. The no treatment control had no mortality and the positive control had
100% mortality after 48 h of observation. The lethal effect was observed when bees were
on their back. Table2-4 shows the effects of SRE, RLZonix and SYRA against honeybees.
The SRE, RLZonix and SYRA were slightly toxic when they were digested by the
honeybees. The percentage of mortality was from 20 to 30% after 48 h observation. In
contrast, the contact exposure test showed that at the same concentrations, the honeybees
were indifferent.
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Discussion

In this work, I studied the antimicrobial activities and the toxicity of SRE, RLZonix
and the mixture (SYRA). As expected, SRE was active against a large array of fungi
including yeasts and filamentous fungi such as C. albicans, Aspergillus spp., and
Penicillium spp. The MIC’s ranged from 1.95-7.8 µg/ml. However, no activity was
observed against bacteria. RLZonix did not show antimicrobial activities against most
tested organisms. The present study is the first report on the antimicrobial activities of
SRE and RLZonix combinations. SRE showed strong synergism with RLZonix for all tested
yeast and fungi. Checkerboard analyses showed that RLZonix reduced the SRE MICs two
to four fold. The FIC indices ranged between 0.25-1 indicating strong synergism between
SRE and RLZonix. It is noteworthy that the strongest activity was observed when RLZonix
and SRE were combined at a 3:1 ratio, respectively. The mixture at this ratio is termed
SYRA. In addition to spore germination inhibition, SRE and SYRA also displayed
antifungal effects against germinated spores and hyphal growth.
Interestingly, RLZonix alone did not exhibit antifungal activity against tested fungi.
However, in the presence of SRE these two showed good synergism.

Antifungal

synergism was previously observed when amphotericin B was combined with gramicidin
S or NF against C. albicans (19). In contrast, Marchetti et al. demonstrated that despite
the antifungal activity of combined Fluconazole and cyclosporine (cy) (FLC) against
C.albicans , the MIC of FLC remained unchanged (22). However, a fungicidal effect
was observed after 48 h of exposure to this combination suggesting that perhaps Cy
action was dependent on the slow effect of FLC on C.albicans cells , and Cy interaction
with the multidrug transporters rendered C.albicans more susceptible to FLC (22). Work
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by Arikan et al. (2) showed favorable interaction between amphotericin B and
caspofungin against Aspergillus and Fusarium spp (2). The combination resulted in a
decrease in amphotericin B MICs (2), and this maybe due to better penetration of
amphotericin B following the effect of caspofungin on the cell wall (2) .
Previous work by Stanghellini (35) showed that RL inhibits zoosporic plant
pathogens by lysing zoospore membranes.

Both SRE and RLZonix

act on the cell

membrane but their mechanism of action are different. The nature of their interaction is
still under investigation. One explanation could be that RLZonix interaction with the
plasma membrane facilitated SRE binding and interaction with the lipid membrane which
resulted in enhancement of channel formation. Another explanation is that perhaps the
anionic characteristic of RLZonix at physiological pH and its interaction with cell surface
provided more negative charges on the surface which allowed more binding and stronger
interaction of SRE with the negatively charged membrane causing an increase in number
of channels formed by SRE. The mechanism of interaction is still under investigation.
I also studied the effect of the addition of RLZonix on the hemolytic activity and
cytotoxicity of SRE. Previous studies by Sorensen et al. (34) and De Lucca et al. (10)
have shown that SRE had hemolytic activity against sheep erythrocytes and toxicity on
HeLa cells.

However, De Lucca and Walsh (11) showed that SRE reduces fungal

viability by 90 to 98% at concentrations that causes 20% release of hemoglobin from
sheep erythrocytes. This result is consistent with my current findings, where SRE MICs
were 3 to 5 times lower than the concentrations that cause 50% of hemolysis and cell
toxicity. In addition, SRE, RLZonix and SYRA effects on honeybees was studied. No
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effects were observed against honeybees at the concentrations that showed hemolytic and
cytotoxicity effects.
In this work, I present the first studies on the antimicrobial activities of SRE and
RLZonix combinations. The in vitro results showed clearly strong synergism between SRE
and RLZonix against phytopathogenic fungi and yeast. The antifungal spectrum and low
toxicity suggests that SYRA is a potential candidate for fungicidal agricultural
applications. However, more work is needed to better understand the mechanism of
interaction in vivo.
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TABLE .2.1. Antimicrobial activities of SRE, RL and SYRA.
ZI (mm)

MIC (µg/ml)

Organism

SRE

RL

SYRA
(SRE/RL)

SRE

SYRA

FIC
index

Aspergillus flavus

7.8

>20

3.9/5.85

11

18

0.5

Rhodotorula
pilimanae
Candida albicans

3.9

93.75

0.97/2.92

22

35

0.24

3.9

>250

1.95/5.85

21

40

0.5

Rhizopus stonifer

7.8

>250

3.9/11.7

11.5

20

0.5

Fusarium
oxysporum
Penicillium sp1

7.8

>250

3.9/11.7

10

17

0.5

7.8

>250

7.8/23.43

10

16

1

Botrytis cinerea

3.9

93.75

0.975/2.92

13

25

0.24

Rhizoctonia solani

3.9

>250

1.95/5.85

10

19

0.5

Cladosporium
cladosporioides
Penicillium
oxalicum
Saccharomyces
cerevisiae W303C
Saccharomyces
cerevisiae
BY4741
Saccharomyces
cerevisiae
8A-1B
Aspergillus niger

3.9

>250

1.95/5.85

15

20

0.5

7.8

>250

1.95/5.85

13

22

0.25

1.97

>250

0.48/1.44

14

25

0.25

1.97

>250

0.48/1.44

13

24

0.25

1.97

>250

0.48/1.44

15

24

0.25

3.9

>250

1.95/5.85

11.5

20

0.5

Staphylococcus
aureus
Bacillus subtilis

>250

>250

>250

>1

>1

ND

>250

>250

>250

>1

>1

ND

Escherichia coli

>250

>250

>250

>1

>1

ND

Proteus vulgaris

>250

>250

>250

>1

>1

ND

MICs values were obtained from triplicate determinations
The zone of inhibition: The error was ± 2 mm, as determined from triplicate determinations.
For FIC index calculations with RL, a value of 250 was used for those organisms with an MIC of >250.
ND, not determined

57

TABLE. 2.2. Hemolytic activity of SRE, RLZonix and SYRA
HD 50% (µg/ml)
SRE

26

RLZonix

75.5

SYRA (SRE)

23

TABLE.2.3. Lethal concentration that caused mortality of 50% of the cells.
Cells
Hek292

3T3

Hela

MDA-MB-435

LC50 (µg/ml)
SRE

96

RLZonix

101

SYRA ([SRE])

28.78

SRE

100.63

RLZonix

95.85

SYRA ([SRE])

25.40

SRE

95.85

RLZonix

96.13

SYRA ([SRE])

26.25

SRE

30.7

RLZonix

41.4

SYRA ([SRE])

12
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TABLE.2.4. Honeybee mortality
A- Contact exposure to SRE and RLZonix .
Time (Hours)
4
12
Concentration
Dead
Live
Dead
Live
(mg/ml)
RLZonix
0
10
1
9
12.5mg/ml
SRE
0
10
1
9
5 mg/ml

B- Feeding SRE and RLZonix
Time (Hours)
4
Concentration
Dead
Live
(mg/ml)
RLZonix
0
10
12.5mg/ml
SRE
0
10
5 mg/ml

D- Contact exposure to SYRA
Time (Hours)
4
Concentration
Dead
Live
(mg/ml)
SYRA
0
10

24

48

Dead

Live

Dead

Live

2

8

2

8

1

9

1

9

12

24

48

Dead

Live

Dead

Live

Dead

Live

2

8

2

8

3

7

1

9

2

8

3

7

12
Dead
0

24
Live

10

Dead
0

48
Live

10

Dead
0

Live
10

(SRE 4.5 mg/ml,
RLZonix 12.5 mg/ml)

C- Feeding with SYRA
Time (Hours)
4
Concentration
Dead
Live
(mg/ml)
SYRA
0
10
(SRE 1.6 mg/ml,
RLZonix 5 mg/ml)

12

24

48

Dead

Live

Dead

Live

Dead

Live

1

9

1

9

2

8

59

B

A

C

FIG.2.1.
Disk diffusion assay testing the combination of SRE with RLZonix.
10 µl of SRE (2.5mg/ml), RLZonix (2.5 mg/ml) and the combination SYRA (0.6mg/ml SRE
and 1.95 mg/ml RLZonix ), SYRA2 (1.95 mg/ml SRE and 0.6 mg/ml RLZonix ) were applied
on disks. A- Botrytis cinerea. B-Candida albicans. C-Schizophyllum commun.
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A

B

Plain agar

Agar contains 10µg/ml
of RLZonix

C

Agar contains 25µg/ml
of RLZonix

FIG. 2.2. Fungicidal activities of different amounts of SRE deposited on PDA containing
RLZonix against R. pilimanae. Different concentrations of SRE were applied to PDA (A) and
Agar containing: 10 µg/ml (B), 25 µg/ml (C) of RLZonix .
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FIG.2.3. SRE and SYRA inhibition against fungal growth. The fungal spores (P. oxalicum, R.
stonifer) were allowed to germinate on PDA plate and grow for 30 h before SRE (0.25mg/ml)
and SYRA (0.25mg/ml SRE and 0.75mg/ml RLZonix ), SYRA
(0.6mg /ml SRE and 1.95mg/ml RLZonix ) were applied on the disks (Column B). Then the
plates were allowed to grow for 24 h. In column A, SRE and SYRA were applied directly after
inoculating the plates with fungal spores. RLZonix showed no inhibition.
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FIG. 2.4. Disk diffusion assay against hyphal extension. The fungal spores were applied
to a filter strip and allowed to grow for 48 h until the appearance of hypae. Then, the
disks were deposited in front of the growing hyphae and 10 µl of SRE (0.25mg/ml) and
SYRA (0.25mg/ml SRE and 0.75mg/ml RL) were applied. The plates were incubated for
another 48 h. RL showed no inhibition.
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FIG. 2.5. Effects of SRE (♦) and SYRA(■) on the viability of C. albicans.
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FIG. 2.6. Time-kill curves of C. albicans. CFU were determined after 3, 6, 9, 12, and
24 h of incubation. Mean CFU values of three separate experiments are shown. Symbols:
SRE (♦), RL (×), SYRA(■), and control(▲)
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FIG. 2.7. Hemolytic activity of SRE (♦), RLZonix (■), and SYRA (▲). The RBCs were
incubated for 1 h at 37°C.
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FIG. 2.8. Percent cytotoxicity of SRE (■), SYRA (▲), and RLZonix (♦).
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CHAPTER 3
PHYSICAL-CHEMICAL PROPERTIES OF SRE AND SRE-RHAMNOLIPID
MIXTURES

Introduction

In recent years, the need for new and effective agrofungicides has emerged due to
decreases in the effectiveness and safety of currently used products (10).
The small cyclic lipodepsipeptide syringomycin E (SRE) contains a long,
unbranched-3-hydroxy fatty acid with a positively charged and hydrophilic cyclic ring of
nine amino acids at the C terminus (5, 13). Previous studies showed that SRE has
inhibitory activity against fungi and yeast such as Botrytis cinerea, Geotrichum candidum
and Rhodotorula pilimanae (9, 17)
The antifungal activity of SRE against a wide range of yeast and fungi, elected it
to be a possible agrofungicide. However, its chances to be developed as a commercial
fungicide agent will strongly depend on its stability under different conditions.
A comprehensive examination of the literature revealed no publications that describe the
chemical stability of SRE over a range of pHs and temperatures. However, Hu et al. (7)
examined the stability of crude extracts of Pseudomonas species under high temperature,
and acidic and alkaline pHs. The results revealed good stabilities of the extract to heat
and acid but not to alkaline pHs (7). Furthermore, based on earlier studies on SRE
activity, it has been observed that SRE solutions had long shelf-lives and remained stable
for years under dry freezing conditions (unpublished observations, J. Takemoto, Utah
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State University). In addition, examination of SRE’s structural features suggests that it
would be relatively stable to different temperatures and acidic pHs.
Rhamnolipids are glycolipids formed by rhamnose linkage to fatty acids of
saturated or unsaturated alkyl chain between C8 and C12 (6). Recent studies have shown
that rhamnolipids are active against zoosporic plant pathogens such as Pythium and
Phytophthora species (16) and against fungal strains such as Fusarium solani and
Penicillium funiculosum (6). In addition, the biosurfactants are known to be effective at
extreme temperature and pH values (2). However, very little information has been
reported on stability of rhamnolipids under different temperatures and pHs. Thaniyavarn
et al. (18) have tested the surface tension activity of rhamnolipids over a wide range of
pHs, temperatures, and NaCl concentrations. The results showed a significant stability of
rhamnolipids over all conditions tested.
SRE and SRE + rhamnolipid (SYRA) formulations are potential candidates for
postharvest disease control and possibly other fungicidal applications in agriculture such
as seed treatment and fruit storage. In Chapter 2, studies on the bioactive properties of
both SRE and SYRA were described. The results showed strong antifungal activities
against yeast and plant pathogenic filamentous fungi. It is important to mention that most
of the experiments were administered in vitro under controlled or optimal conditions.
However, if used in the field these compounds may be exposed to proteolysis and variety
of environmental and climate conditions such as high temperatures, humidity and
different pHs that may abolish or alter their antifungal activities. Their usefulness as
agrofungicides requires sufficient stability when subjected to such conditions.
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The aim of this study is to examine the physical and chemical stability of SRE
and SYRA. To further explore their stabilities and candidacies as agrofungicides, SRE
and SYRA formulations were exposed to different temperatures and pHs, and subjected
to autoclaving, ultraviolet light, sonication, and proteolysis. The treated solutions were
tested for antifungal activities and analyzed by RP-HPLC in the cases of temperature and
proteolysis treatments. In addition, SRE and SYRA were mixed with mineral oil and
their activities were tested. The overall results showed significantly high stability of SRE
and SYRA under the tested conditions.

Materials and Methods

SRE and SYRA
SRE was purified from P.syringae pv.syringae strain B301D by the method of
Bidwai et al. (3). P.syringae pv.syringae strain B301D was grown in non-commercial
potato dextrose casamino acids medium in 4- or 8-liter cultures as described by Zhang
and Takemoto (19). The SRE was extracted from cultures using acidified acetone and
purified using the chromatographic methods described by Bidwai et al. (3). HPLC
column fractions were tested for bioactivity by applying 10 µl aliquots on a fresh lawn of
R. pilimanae on potato-dextrose agar plates, incubation at 28oC, and observing cleared
growth inhibition areas (19). Commercial rhamnolipid (Zonix) (RLZonix) was obtained
from Jeneil Biotech, Inc. RLZonix is an 8.5% (wt/vol) solution of rhamnolipid analogs in
water. Two forms of rhamnolipids are in RLZonix, R1 (C26H48O9) has the molecular
formula of α-L-rhamnopyranosyl-β-hydroxydecanoyl-β-hydroxydecanoate, and R2
(C32H58O13)
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is 2-O-α-L-rhamnopyranosylα-L-rhamnopyranosyl- β hydroxydecanoate. SYRA was
prepared by combining SRE and RLZonix at 1:3 (wt/wt) ratios, respectively.
formulations were used: SYRA0.6,

1.95

Two

(0.6 mg SRE and 1.95 mg RLZonix per ml) and

SYRA0,25,0.75 (0.25 mg SRE and 0.75 mg RLZonix per ml).

Antifungal Activities
Agar disk diffusion method. The disk diffusion assay was done accordingly to
the method described by the National Committee for Clinical Laboratory Standards (1)
protocols for antifungal testing with modification (11, 15) . R .pilimanae was grown in
potato dextrose broth (PDB) and adjusted to 5×104 CFU/ml (8, 14) , and transferred onto
solid agar medium. The culture was spread over the surface as a thin film (14). Four mm
diameter sterilized paper disks were deposited on the surface and SRE and SYRA0.6,1.95 or
SYRA0,25,0.75 were applied on disk1 and disk 2, respectively (7 to 10 µl aliquots).
HPLC analysis. The high performance reverse-phase liquid chromatography
(RP-HPLC) analysis was performed by the method determined by Bidwai et al. with
modification (3). The treated SRE and SYRA were loaded onto C18 reverse-phase
column for HPLC analysis. The samples were eluted by a 25 min (0.5ml per min) linear
gradient of the 70% of 0.1% trifluoroacetic acid in water, and 30% of 0.1%
trifluoroacetic acid in isopropanol. Eluted SRE and SYRA were detected by UV
detection at 240 nm.
Effect of temperature. SRE (1mg/ml) and SYRA0.25,0.75 solutions were prepared
and incubated at 4°, 28°, 50°, and 65°C. At 50°C, and 65°C the activities were tested as
described previously every day for 17 days. At 4°C and 28°C the activities were tested
each day for 60 days. The solutions were also autoclaved for 15, 30 and 45 min and their
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activities were tested against R .pilimanae and 50 µl of the treated SRE solutions or
SYRA0.25,0.75 were analyzed by RP-HPLC as described previously (3). In the case of
SYRA0.25,0.75 , two sample variations were prepared and used in these experiments.
Sample A was prepared by mixing SRE (0.25mg/ml) and RLZonix (0.75 mg/ml) after
autoclaving the individual solutions separately. Sample B was prepared by mixing SRE
(0.25 mg/ml) and RLZonix (0.75 mg/ml) before autoclaving.
Effect of pH on SRE and SYRA activity. The effect of pH on the activities of
SRE (2.4 mg/ml) and SYRA0.6,1.95 was examined using the disk diffusion assay against R.
pilimanae as described before (12). The solutions were adjusted to pH values of 4, 5, 6,
and 7 by the addition of 1N HCl or 1N NaOH and incubated at room temperature for 24
h. Ten µl of SRE and SYRA0.6,1.95 were applied on the disks. The plates were incubated
at 28oC for 48 h and the zones of inhibition were measured.
Effects of ultraviolet light and sonication
on SRE and SYRA activities. The effects of UV light and sonication on SRE
and SYRA activities were studied using the disk diffusion assay against R .pilimanae
(12). One hundred µl SRE (2.4 mg/ml) and SYRA0.6,1.95 were added to 96 well-plates
and irradiated using a Fisher Biotech ultraviolet hand-held lamp (Fisher Scientific) for 60
min at a wave length of 320 nm. Ten µl of SRE (2.4 mg/ml) and SYRA0.6,1.95 were taken
every 10 min for 60 min and applied on disks. The plates were incubated at 28°C for 48
h and the zones of inhibition were measured.
Two hundred µl of SRE (2.4 mg/ml) and SYRA0.6,1.95 in 2 ml glass tubes were
sonicated for different time intervals in a water bath sonicator ( Bransonic ultrasonic
Model 1210, 50-60Hz). The 10 µl samples were taken every 10 min for 60 min and
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tested for activity as described previously. The plates were incubated at 28°C for 48 h
and the zones of inhibition were measured.
Trypsin treatment. To study the effect of protease on SRE and SYRA activities,
the solutions were dissolved in PBS buffer, pH 7.4 in 1.5 mL capacity microcentrifuge
tubes (20). Trypsin (bovine pancreas, Sigma, St. Louis) was added at ratio of 1:25
(enzyme/peptide, w/w). SRE (1mg/ml) and SYRA0.25,0.75 were mixed with 40 µg/ml and
10 µg/ml of trypsin, respectively. The tubes were incubated at 37°C for 2 h and stopped
by adding trypsin inhibitor aprotinin (Sigma) (10µg/ml). The treated samples were
examined for their activities against R .pilimanae and analyzed by RP-HPLC as described
earlier.
Effect of mineral oil on SRE and SYRA
activities. SRE and SYRA0.25,0.75 were mixed with mineral oil at a ratio of 1:1
(vol/vol) and incubated at room temperature for 1 h. Ten µl of SRE and SYRA0.25,0.75
were tested by disk diffusion assay as described earlier. The plate was incubated at 28°C
for 48 h and the zones of inhibition were measured.

Results and Discussion

Physico-chemical Stability of SRE and SYRA
The use of SRE and SYRA as fungicides agents requires that they be sufficiently
stable. Their useful applications will necessitate long-term stability, as well as resistance
to environmental conditions such as temperature, ultraviolet light, and pH variations.
The results show that SRE and SYRA0.25,0.75 are stable at 4°C and 28°C (Fig. 3.1).
However, at 55°C and 65°C, SYRA0.25,0.75 activity began to decrease after 4 days and
was completely lost after 6 and 11 days at 65°C and 55°C, respectively (Fig. 3.1). In
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contrast, SRE remained completely active at these temperatures. It is important to note
that at 4°C and 28°C SRE and SYRA0.25,0.75 activities were very stable after 60 days of
incubation (data not shown).
To further explore the effect of temperature on SRE and SYRA0.25,0.75 activities.
SRE and SYRA0.25,0.75 were autoclaved for 15, 30, and 45 min at 121°C (Table. 3.1, Fig.
3.2). SRE showed full inhibitory activity against R . pilimanae at each time. In contrast
the activity of SYRA0.25,0.75 (sample B) declined when autoclaved. However, when
SYRA0.25,0.75

prepared with separately autoclaved solutions of SRE and RLZonix (sample

A), it was active. To further examine the effect of autoclaving on SRE and SYRA0.25,0.75
HPLC analyses were performed on treated samples (Fig. 3.3.). HPLC profiles of RLZonix
showed that its structure was not affected by autoclaving. However, 60 % of SRE was
degraded. as a consequence of autoclaving. In the case of sample B, the SRE structure
was completely degraded (Fig. 3.3). It appears that RLZonix interaction with SRE forms a
complex that is heat sensitive. It could be speculated that the two molecules physically
interacted via their hydrophobic and hydrophilic moieties, respectively, and that high heat
(e.g. autoclaving) disrupts the interactions that are mainly hydrophobic interactions and
hydrogen bonding. SRE and RLZonix each showed significant long term stability. In the
case of SYRA0.25,0.75, the long term stability was very good at 4°C and 28°C, but, the
stability began to decline at 55°C and 65°C. These observations are important for
considerations of storage and transportation of SYRA formulations.
To further explore the physical properties of SRE and SYRA0.6,1.95 , these two
were exposed to UV light, sonication, and varied pHs levels. The results showed UV
light and sonication had no effects on antifungal activities against R. pilimanae were not
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affected by UV light (Fig. 3.5). SRE and SYRA0.6,1.95 antifungal activities were also
stable at pHs between 4 and 7 (Fig. 3.4). However with SYRA0.6,1.95, I observed a
moderate increase in activity at pH 5 and 6 (Fig. 3.4). This difference in activity is
perhaps due to the net charge of RLs. RL is a anionic biosurfactant with a pKa value of
5.6 (2). It was reported by Aranda et al. (2) that at pH 7.4, 98.4 % of the rhamnolipid
forms are negatively charged, whereas, at pH 4, 97 % are neutral. Possibly, the ratio
between the anionic and neutral forms have contributed to the activity of SYRA0.6,1.95.
This information is important for considering pH constraints when combining SRE and
RLZonix to make SYRA formulations for applications. The overall results indicate a good
degree of stability for both SRE and SYRA0.6,1.95 at pH range of 4 to 7.
The successful use of SRE and SYRA formulations as fungicidal agents may
depend on environmental and climate conditions such as humidity, radiation, and
temperature. Wet and humid conditions may require repetitive treatments to reach the
desired control.

In addition, this may enhance the effectiveness of fungicides by

facilitating its spread and penetration into the pathogen. However, repetitive applications
might be costly. Perhaps using mineral oil to deliver these agents may reduce the cost.
SRE and SYRA were mixed with mineral oil and tested for activity against R. pilimanae .
The results showed that SRE and SYRA0.25,0.75, were active after mixing them with
mineral oil (Table. 3.2.).

Effects of Trypsin
To examine whether SRE and SYRA formulations are stable to protease
treatment, SRE and SYRA0.25,0.75 were pretreated with trypsin and their antimicrobial
activities were tested. The results showed that trypsin treatment did not alter SRE and
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SYRA0.25,0.75 activities against R. pilimanae. Moreover, no degradation was observed in
the tryspin-treated samples. HPLC analyses showed that the peaks were almost identical
to the control (Fig. 3.6). The trypsin is known to cleave at the carboxyl side of both
lysine and arginine that are connected to other amino acids. Interestingly, trypsin did not
cleave the Arg-Phe bond in SRE. Perhaps the nine amino acids cyclic ring and the
structural conformation of SRE prevented and protected the molecule from trypsin active
site. This result is consistent with observations of Fernandez-Lopez et al. (4) on
chemically synthesized cyclic D,L-alpha-peptides.
In conclusion, the results of this study provide information on the activities and
chemical stabilities of SRE and SYRA formulations under a variety of physical
conditions and chemical treatments.

Overall, SRE and the SYRA show long term

stabilities. Their broad spectrum antifungal properties and physical stabilities reinforce
the prediction that they are promising candidates for use as agrofungicides.
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Table. 3.1. Effect of autoclaving on SRE and SYRA0.25,0.75 activities

Autoclave time

Zone of inhibition (mm)
15 minutes
30 minutes

45 minutes

2.4mg/mlSREAutoclaved

22

20

20

SYRA0.25,0.75
Mixture B

NI

NI

NI

2.6mg/ml RL
Autoclaved

NI

NI

NI

SYRA0.25,0.75
Mixture A
NI= no inhibition

34

32

29

Table.3.2. Effect of mineral oil on SRE and SYRA0.25,0.75 activities.
Zone of inhibition (mm)
SRE

SYRA0.25,0.75

With mineral oil

22

35

Without mineral oil

22

35
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Fig. 3.1. Effect of temperature on SYRA0.25,0.75 activity 4°C(■) , 28°C(♦) , 55°C(●) ,
65°C(▲).SRE activity (○) 4°C , 28°C , 55°C , 65°C ( SRE activity was the same for all
temperatures)
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Fig. 3.2. The antifungal activity of SRE, RL, and SYRA against R .pilimanae.after
autoclaving. Ten µl of SRE, RL, SYRA0.25,0.75 mixture A (SYRA) prepared after
autoclaving the components SRE and RL Zonix and SYRA0.25,0.75 mixture B (SYRA’)
mixed before autoclaving) were applied on disks placed on a lawn of
R .pilimanae.
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Fig. 3.3. HPLC analyses of : (A) SRE 1mg/ml, (B) RLZonix 0.75mg/ml (the arrows
represent rhamnolipid isomers RL1 and RL2), and (C) SYRA0.25,0.75 . (---)
before autoclaving and (−
−) after autoclaving. Shown are the HPLC profiles
obtained using a C18 column with a 25 minute of 0-70% gradient 2-propanol in
0.1% TFA.
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Fig. 3.4. The effect of pH on SRE (█), and SYRA0.6,1.95 (▓) antifungal activity against
R .pilimanae
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Fig. 3.5. Effect of UV exposure and sonication on SRE and SYRA0.6,1.95 activities.
SRE: UV exposure (●), sonication (○). SYRA0.6,1.95: UV exposure (■), sonication (□)
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Fig. 3.6. HPLC analyses of (A) SRE (1mg/ml) and (B) SYRA0.25,0.75 before trypsin
treatment (---) and after trypsin treatment (−). Shown are the Shown are the HPLC
profiles obtained using a C18 column with a 25 minute of 0-70% gradient
2-propanol in 0.1% TFA.
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CHAPTER 4
MECHANISM OF ACTION OF SRE- RLzonix COMBINATION

Introduction

Syringomycin

E

is

a

cyclic

lipodepsinonapeptide

produced

by

the

phytopathogenic strains of Pseudomonas syringae pv. syringae (Takemoto, 1992). SRE
has inhibitory activity against fungi and yeast such as Botrytis cinerea, Geotrichum
candidum and Rhodoturula pilimanae (Takemoto et al., 1992; Lavermicocca, et al.,
1997). The mechanism of action of SRE is well studied. SRE acts on yeast and plant
plasma membranes to cause numerous cellular effects with increases in cellular K+ efflux
and transient Ca2+ fluxes among the most prominent. The effects are consistent with
SRE’s ability to form ion-conducting voltage sensitive channels in membrane bilayers.
However, ion channel formation in the native plasma membrane as the primary cause of
growth inhibition has not yet been determined.

In addition, studies with lipid

biosynthesis yeast mutants have revealed that sphingolipids and sterols modulate the
fungicidal activity of SRE (Cliften et al., 1996; Grilley et al., 1998; Stock et al., 2000).
For instance, among the genes that promote SRE action, the SYR2 is gene required for
sphingolipid C-4 hydroxylation, ELO2 and ELO3 are responsible for very long fatty acid
elongation, FAH1, responsible for α-hydroxylation of the amide linked very long chain
fatty acids, and IPT1, which encodes the enzyme that catalyzes the terminal yeast
sphingolipid biosynthetic step (Cliften et al., 1996, Grilley et al., 1998; Stock et al.,
2000). In addition, SMR1 (identical to ERG3), which encodes the C-5,6 desaturase
required for ergosterol biosynthesis (Taguchi et al., 1994) is also needed for SRE action.
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SRE lipidic pore formation has been proposed as the mechanistic basis for SRE action on
membranes (Malev et al., 2002).
Rhamnolipids are produced by Pseudomonas aeruginosa and are formed by
rhamnose linkage to fatty acids of saturated or unsaturated alkyl chain between C8 and
C12 ( Haba et al., 2002). Rhamnolipids possess antimicrobial activities ( Haba et al.,
2002). They are active against zoosporic plant pathogens (Stanghellini et al, 1997) and
other fungal species such as Fusarium solani and Penicillium funiculosum ( Haba et al.,
2002).

The mechanism of action of rhamnolipids against fungi is still unknown.

However, Stanghellini and Miller (Stanghellini & Miller, 1997) suggested that the
rhamnolipids inhibit the zoosporic fungi by disrupting the zoospore plasma membrane.
Combinations of existing fungicides show some promise for use as next
generation and more effective antifungal strategies (Rex et al., 1995). The current work
is part of a general study on the antifungal properties and efficacy of combined SRE and
RL zonix formulations. I hypothesize that SYRA the combination of SRE and RLzonix also
inhibit fungi by mechanisms that are similar to those for SRE action. Therefore, I studied
the effects of SYRA on Saccharomyces cerevisiae strains deficient in various steps of
sphingolipid and sterol biosynthesis to investigate whether the antifungal action of
SYRA, like SRE, depends on sphingolipids and sterols.
To further examine the basis for the fungicidal activity of SYRA, I studied the
channel-forming properties of SRE, RLzonix , and SYRA in lipid bilayers in comparison
with those of SRE. The results suggest that sphingolipids and sterols are important for
the killing action of SYRA in a manner similar to the mechanism of action of SRE, and I
found that SYRA and SRE have similar single-channel pore forming properties.
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Materials and Methods

SRE and SYRA
SRE was purified from P.syringae pv.syringae strain B301D by the method of
(Bidwai et al., 1987). P.syringae pv.syringae strain B301D was grown in noncommercial potato dextrose casamino acids medium in 4- or 8-liter cultures as described
by Zhang and Takemoto (1987). The SRE was extracted from cultures using acidified
acetone and purified using the chromatographic methods described by Bidwai et al
(Bidwai et al., 1987). HPLC column fractions were tested for bioactivity by applying 10
µl aliquots on a fresh lawn of R. pilimanae on potato-dextrose agar plates, incubation at
28oC, and observing cleared growth inhibition areas (Zhang & Takemoto, 1987).
Commercial rhamnolipid Zonix (RLZonix) was obtained from Jeneil Biotech, Inc. RLZonix
is an 8.5% (wt/vol) solution of rhamnolipid analogs in water. Two forms of rhamnolipids
are in RLZonix, R1 (C26H48O9) has the molecular formula of α-L-rhamnopyranosyl-βhydroxydecanoyl-β-hydroxydecanoate,
rhamnopyranosylα-L-rhamnopyranosyl- β

and

R2(C32H58O13)

hydroxydecanoate.

is

2-O-α-L-

A formulation was

prepared by combining SRE and RLZonix at 1:3 (wt/wt) ratios (0.25 mg SRE and 0.75 mg
RLZonix per ml), respectively, and designated SYRA0,25,0.75.

Yeast strains and maintenance
SRE-sensitive S. cerevisiae strains 8A-1B, W303C, and BY4741 and isogenic
SRE-resistant and lipid biosynthesis mutant strains ∆erg3, ∆syr2, ∆ipt1, ∆elo2, ∆elo3,

∆skn1 and ∆fah1 were described previously. SRE-resistant strains ∆syr2 and ∆elo3 are
single-gene disruptants isogenic to parental strains W303C and 8A-1B, respectively. All
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other SRE-resistant mutants are single gene disruptants isogenic to parental strain
BY4741. The strains were grown at 28°C and maintained at 5oC in yeast extract-peptone
dextrose (YPD) broth or on agar medium (Hama et al., 2000).

Effects on yeast growth
Replica plating. The effects of SRE, RLZonix , and SYRA0,25,0.75 on the growth of
yeast strains were determined using the replica plate method as previously described
(Hama, et al., 2000). Freshly grown cells of yeast parental and lipid mutant strains were
replica-plated onto YPD agar containing different concentrations of SRE, RLZonix , and
SYRA0,25,0.75 and incubated for 2 to 3 days at 28°C. Growth was determined by visual
inspection of the agar plates.
Disk diffusion assay. The disk diffusion assay was done accordingly to the
method described by the National Committee for Clinical Laboratory Standards
(NCCLS) protocols for antifungal testing with modification (NCCLS, 1997,2002).
Different yeast parental and lipid mutant strains were grown on YPD for 48 h at 28°C
and 50 µl of cell suspension was transferred and spread uniformly using a cotton swab
onto YPD agar (Steinbach et al., 2004). Four mm diameter sterilized paper disks were
deposited on the surface and 10 µl of SRE (0.25 mg/ml), RLZonix (0.75 mg/ml), and
SYRA0,25,0.75 were applied onto each disk. The plates were incubated for 24 to 48 h and
the zones of inhibition were measured.
Microbroth dilution assay.

Minimal inhibitory concentrations (MICs) were

determined by the microbroth dilution assay according to methods outlined by the
NCCLS with modification (NCCLS, 1997, 2002). Yeast parental and lipid mutant strains
were grown to a final concentration of 108 CFU/ml and suspended at a final concentration
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of 5 x105 CFU/ml. Cell suspensions (25 µl ) were added to 25µl aliquots of twofold serial
dilutions of SRE, RLZonix , and SYRA0,25,0.75 and YPD broth media were dispensed (100
µl total volume) in wells of 96-well polystyrene microtiter plates (Fisher Scientific,
catalog no. 21-377-203). The plates were incubated for 24 h at 28°C. The MICs were
determined by visual inspection of the 96-well plate.

Lipid bilayer channel formation
Lipid bilayer electrophysiological experiments were performed using 1,2dioleoyl-sn-glycero-3-phosphorylcholine (DOPC), (Avanti Polar Lipids) as previously
described (Blasko et al., 1998, Malev et al., 2002). Solutions of 0.1 M of NaCl were
buffered with 5 mM MOPS (Sigma) to pH 6. Bilayer lipid membranes were prepared by
the monolayer-opposition technique (Montal & Muelle; 1972) on a 50–100 µm diameter
aperture in the 10 µm thick Teflon film separating two (cis and trans) compartments of a
Teflon chamber (Montal & Mueller et al., 1972; Bezrukov & Vodyanoy, 1993). The
membrane-forming solution was DOPC. A pair of Ag/AgCl electrodes with agarose/2 M
KCl bridges was used to apply transmembrane voltages and to measure single channel
currents. Current measurements were carried out using an Axopatch 200B amplifier
(Axon Instruments) in the voltage clamp mode. The data were filtered with a low-pass 8pole Model 9002 Bessel filter (Frequency Devices) at 1 kHz and directly recorded into
computer memory with a sampling frequency of 5 kHz. Data were analyzed using
pClamp 9.2 (Axon Instruments) and Origin 7.0 (Origin Lab).

Single channel

conductance was calculated as the mean single-channel current divided by the applied
transmembrane voltage. All experiments were performed at room temperature.
SRE (5 µg/ml ) and RLZonix (4 µg/ml) were added to the aqueous phase as follows :
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1- At t=0, SRE was added to cis side compartment
2- At t=0, RLZonix was added to cis side compartment, then at t=10 min, SRE was
added to the same side.
3- At t=0, SRE was added to the cis side compartment, then at t=10 min, RLZonix
was added to the opposite side trans side.
4- At t=0, RLZonix was added to the trans side, then at t=10 min, SRE was added to
the trans side.

Results

Susceptibility of SRE-resistant lipid
biosynthesis mutants
The growth of S. cerevisiae sphingolipid and sterol biosynthetic mutants in the
presence of different concentrations of SRE and SYRA0,25,0.75 was examined. On replicaplated YPD agar medium SRE (0.75 µg/ml) and SYRA0,25,0.75 (0.5µg/ml of SRE and 1.5
µg/ml of RLZonix) inhibited the growth of parental yeast strains (W303C, BY4741, and
8A-1B) (Fig. 4.1) but not the lipid mutant strains ( Fig. 4.2). SYRA0,25,0.75 was the most
effective inhibitor against the S. cerevisiae strains (Table. 4.1, Fig. 4.2). The MICs (of
equivalent SRE levels in SYRA0,25,0.75) were 2 to 4 fold lower than the SRE MICs (of
SRE alone) (Table. 4.1) against all S. cerevisiae strains tested. Although all of the
mutants were less susceptible to the SRE and SYRA0,25,0.75 compared to their parental
strains, there was some variation in the extent of resistance among the tested mutants. For
example, the corresponding SRE-resistant isogenic mutant strains with deletions in genes
for sphingolipid (∆syr2, ∆ipt1, and ∆skn1) or ergosterol (∆erg3) biosynthesis were less
susceptible to inhibition by SYRA0,25,0.75 compare to the other mutants ( ∆fah1, ∆elo3,
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and ∆elo2). However, in the case of SRE, ∆syr2 and ∆erg3 were the most resistant
compared to the other strains. Overall, the patterns of relative susceptibility and
resistance of the lipid mutants to SYRA0,25,0.75 and SRE were similar. At relatively high
concentrations of SRE (3.9 µg/ml) and SYRA0,25,0.75 (1,95µg/ml SRE and 5,85 µg/ml
RLZonix ) neither the wild type nor the mutants grew.

Ion channel formation
To study the influence of RLZonix on SRE interaction with the plasma membrane,
I examined the membrane channel forming properties of SRE in the presence and
absence of RLZonix. The effects on ion conductance across planar lipid bilayers were
measured. Figure. 4.3 shows time courses of the integral macroscopic conductance of the
bilayers doped with SRE alone and SRE with RLZonix.
The results showed that the negative potential application drove the increase of
the membrane conductance. Remarkably, the addition of RLZonix to both sides of the
bilayer (cis and trans) caused a significant increase in membrane conductance indicating
an increase in the number of pores formed by the combined mixture of SRE and RLZonix.
However, after 40 min of the imposing voltage, the conductance decreased indicating the
closing or disappearance of the pores. As reported previously (Szabo et al., 2004)
(Malev et al., 2002), SRE produced a smaller steady-state conductance and no
subsequent decrease was observed after 40 min. No change in conductance was observed
when RLZonix was applied alone.

In contrast to the differences in macroscopic

conductance, the properties of the transmembrane single channels formed by SRE with or
without RLZonix were the same (Fig. 4.3).
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Discussion

It is known that SRE interacts with membranes resulting in lipidic pore formation
that in yeast leads to ion leakage, membrane dysfunction, and possibly other cell
damaging effects. It is also known that growth inhibition by SRE is modulated by
sphingolipids and sterols (Grilley et al., 1998; Cliften et al., 1996; Stock et al., 2000;
Hama et al., 2000) Sphingolipid and sterol biosynthetic mutants of yeast were less
susceptible to SRE as compared to the isogenic wild type strains. The same effect was
observed with SYRA. However, the presence of RLZonix rendered the wild type and the
mutants cell more sensitive to SRE. the effect was greatest in yeast with mutations in
either SYR2, the gene responsible for C4 hydroxylation of sphingolipids, or SMR1,
which encodes the C-5, 6 desaturase required for ergosterol biosynthesis. It is unclear
whether the RLZonix interaction with the plasma membrane was affected by the
sphingolipid and sterol biosynthetic mutation such as the lack of C-4 hydroxylation or
C5, 6 desaturase as it was shown for SRE action. However, the presence of RLZonix
facilitated SRE binding to the plasma membrane. Thus, SRE was more effective and it
increased its activity.
To further explore and understand the effect of RLZonix on SRE action, the
transmembrane channel properties of SRE+ RLZonix were examined and compared to
those of SRE channels.

SRE caused voltage-dependent macroscopic conductance

increases due to the formation of ion permeable channels in the membrane bilayers.
However, when RLZonix was added, a significant increase in the conductance level was
observed. This increase is mainly due to the total numbers of channels formed. I suggest
that the observed increase in the number of channels is due most likely to the
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enhancement and favorable binding of SRE in the presence of RLZonix. However, after 40
min a decrease in conductance was observed as a consequence of pore inactivation in the
planar membrane. This perhaps is triggered by the dissociation of SRE+ RLZonix complex
from the plasma membrane. The nature of interaction between SRE, RLZonix, and the
plasma membrane, however, is not clear. One possibility is that the penetration of RLZonix
into the plasma membrane (in which the hydrophobic portion interacts with lipids and the
negatively charged polar head points outward in a carpet-like manner (Oren & Shai,
1998) attracts more SRE binding to the membrane to give an increase in number of
channels (Fig. 4.4). It is important to mention that the nature of the membrane plays an
important role in how RLZonix binds and inserts into the membrane (Aranda, et al., 2007).
Aranda, et al., (2007) suggested that a high presence of cholesterol in the membrane
rendered the binding of diRL more difficult; however, the presence of
phosphatidylethanolamine enhanced its binding and partitioning into the membrane.
Another possibility is that SRE interacts with the plasma membrane with a barrel-stave
mechanism as described by Oren et al. (1998) for linear amphipathic peptides. The
positive charge of the SRE polar head and pore formation results in a decrease in the
motional order of the lipids and as a consequence, RLZonix binding and insertion into the
membrane is enhanced (Aranda et al., 2007) with an increase in the number of channels.
In summary, the present study suggests that SYRA inhibits yeast by the same
mechanism as does SRE by itself. Its antifungal action is promoted by sphingolipids and
sterols of the plasma membrane and involves pore formation. The results also provide an
explanation for the antifungal synergy between SRE and RLZonix. The addition of RLZonix
results in an increase in the number of membrane channels formed by SRE.
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Table. 4.1 Antimicrobial activities of SRE and SYRA against yeast lipid
biosynthetic mutants.
Organisms
Zone of inhibition
MIC (µg/ml)
(mm)
Saccharomyces
cerevisiae
W303C
∆syr2
∆elo3

SRE

SYRA

SRE

14
10
14

25
7
19

0.97
3.9
1.95

SYRA
(SRE/ RLZonix )
0.48/1.44
1.95/5.85.
0.97/2.91

BY4741
∆ipt1
∆fah1
∆elo2
∆skn1

13
12
12
12
12

24
17
22
22
22

0.97
1.95
1.95
1.95
1.95

0.48/1.44
1.95/5.85
0.97/2.91
0.97/2.91
0.97/2.91

∆8A-1B
15
24
0.97
0.48/1.44
∆smr1
10
8
3.9
1.95/5.85
MICs values were obtained from triplicate determinations
The zone of inhibition: The error was ± 2 mm, as determined from triplicate
determinations
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Control

SRE 0.75µg/ml

SYRA 0.5µg/ml, 1.5µg/ml

Fig. 4.1 .Effect of SRE and SYRA on growth of yeast lipid biosynthetic mutants.
Sphingolipid and ergosterol biosynthesis mutant and parental strains were replica plated
onto YPD agar with or without: SRE (0.75µg/ml) or SYRA (0.5µg/ml SRE, 1.5µg/ml
RL) the plates were incubated at 28°C for 48 h.
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SRE

SYRA0,25,0.75

Fig. 4.2 . SRE and SYRA0,25,0.75 inhibition against yeast lipid biosynthetic mutants. Ten µl
of SRE (0.25mg/ml) and SYRA0,25,0.75 were applied on the disks. The plates were incubated
for 48 h. RLZonix showed no inhibition.
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FIG.4.3. Time course of ion conductance of bilayers doped with A)- SRE, B)- SRE and
RL applied to Cis side. C)- SRE applied to cis side and RL to trans side , recorded at the
applied voltage of –50 mV
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Fig. 4.4. A cartoon illustrating on the mechanism of SRE and RL combination and
membrane pore formation. Red symbol represents RL and blue symbol represents SRE.
Left: A- the RL interacted with the plasma membrane with their hydrophobic embedded
in the membrane and hydrophilic portion on the surface. B- the binding of RL attracted
more SRE to the surface of the plasma membrane. Right: A-the syringomycin interacts
with the plasma membrane. B- The binding of SRE resulted in channel formation and a
decrease in the motional order of the lipids as a consequence, RLZonix binding and
insertion into the membrane is enhanced with an increase in the number of channels.
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CHAPTER 5
MECHANISMS OF YEAST GROWTH INHIBITION
BY SYRINGOPEPTINS

Introduction

In addition to well-characterized cyclic lipodepsinonapeptides, Pseudomonas
syringae pv. syringae produces larger cyclic lipodepsipeptides known as the
syringopeptins (SPs). These compounds are composed of 22 or 25 amino acids (SP22 and
SP25, respectively) with an octadepsipeptide ring structure and a 3-hydroxy fatty acyl
chain. Isoforms of SP22 and SP25 possessing fatty acyl chains composed of ten and
twelve carbons are designated A and B homologs, respectively. The SPs are phytotoxic,
and they have antimicrobial activities against Gram-positive bacteria (Lavermicocca et
al., 1992; Grgurina et al., 2005, Chapter 6). They are also antifungal although typically
less potent in this regard than the cyclic lipodepsinonapeptides (Iacobellis et al. 1992;
Lavermicocca et al., 1997; Grgurina et al., 2005). Nevertheless, SP22 analogs show
strong inhibitory activities against certain fungal yeasts including the pathogen Candida
albicans (Grgurina et al., 2005).
The mechanisms of action of the cyclic lipodepsinonapeptides, particularly
syringomycin E (SRE), are well studied. SRE acts on yeast and plant plasma membranes
to cause numerous cellular effects with increases in cellular K+ efflux and transient Ca2+
fluxes among the most prominent. The effects are consistent with SRE’s ability to form
ion-conducting voltage sensitive channels in membrane bilayers. However, ion channel
formation in the native plasma membrane as the primary cause of growth inhibition has
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not yet been determined. In addition, studies with yeast have revealed that sphingolipids
and sterols (lipids that occur predominantly in the plasma membrane) modulate the
fungicidal activity of SRE (Cliften et al., 1996; Grilley et al., 1998; Stock et al., 2000).
SRE lipidic pore formation has been proposed as the mechanistic basis for SRE action on
membranes (Malev et al., 2002). Less is known of the mechanisms of action of the SPs.
A few studies have shown that the SPs are capable of forming ion conducting membrane
channels (Hutchison & Gross, 1997; Dalla Serra et al., 1999; Agner et al., 2000). In lipid
bilayers and erythrocytes, SP22A channels do not thermally inactivate as do SRE
channels – a phenomenon related to SP22A’s greater effectiveness in ordering membrane
lipids (Szabo et al., 2004). In plant systems, SPs have been shown to cause electrolyte
leakage in leaf tissues (Iacobellis 1992; Lavermicocca et al., 1997), to increase the
permeability of tonoplasts (Carpaneto et al., 2002), close stomata (Di Giorgio et al.,
1996) and modify H+ fluxes across mitochondria and plasma membranes (Di Giorgio et
al., 1994;1996). Finally, SPs interact with bacterial cell surface teichoic acids (Chapter
6Bensaci), but the mechanism of interaction with bacterial membranes is still unknown.
Despite recognition that the SPs have antifungal activities, there have been no published
studies on the mechanisms of action of SPs against yeasts or other fungi.
In this study, we address the mechanisms of action of SPs against yeast. We show
that the physiological responses of yeast to the SPs and the membrane lipid requirements
for fungicidal action resemble those of SRE. This is so despite the large structural
differences between the SPs and SRE molecules. To examine the basis for the fungicidal
activity of SPs, we studied the channel-forming properties of the SPs in lipid bilayers in
comparison with those of SRE. We found that SP22A and SP25A produce higher
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macroscopic conductance than SRE but, surprisingly, have similar single-channel
properties.

Materials and methods

Yeast strains and maintenance
Saccharomyces cerevisiae SRE-sensitive strains KZ1-1C, 8A-1B, W303C, and
BY4741 and SRE-resistant and lipid biosynthesis mutant strains ∆erg3, ∆syr2, ∆ipt1,

∆elo2, ∆elo3 and ∆fah1 were described previously (Taguchi et al., 1994, Hama et al.,
2000, Stock et al., 2000). SRE-resistant strains ∆erg3 (formerly ∆syr1, (Taguchi et al.,
1994)) and ∆fah1 are single-gene disruptants isogenic to parental strains 8A-1B and
BY4741, respectively.

All other SRE-resistant mutants are single gene disruptants

isogenic to parental strain W303C. The strains were grown (28°C) and maintained (5oC)
in yeast extract-peptone dextrose (YPD) broth or on agar medium (Hama et al., 2000).

Purification of SRE, SP22A and SP25A
SRE was purified from Pseudomonas syringae pv. syringae strains B301D or M1
by previously described methods of (Bidwai et al., 1987; Adetuyi et al., 1995). SP22A
and SP25A were purified from extracts of strains P. syringae pv. syringae B301D and
M1 respectively, using methods described earlier (Chapter 6).

Effects on yeast growth
The effects of SP22A, SP25A and SRE on the growth of yeast strains were
determined using two methods. A replica plate method was used as previously described
(Hama et al., 2000). Freshly grown cells of yeast parental and lipid mutant strains were
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replica-plated onto YPD agar medium containing different concentrations (between 0.61
and 2.06 uM) of SRE, SP22A, and SP25A and incubated for 2 to 3 days at 28°C. Growth
was determined by visual inspection of the agar plates. For measuring effects on growth
in liquid batch cultures, parental yeast strain KZ1-1C was first grown in YPD broth
medium at 28°C in 125 mL capacity Erlenmeyer flasks with rotary shaking for 48h to a
density of ~8 x 108 cells ml-1. The cells were centrifuged and resuspended in YPD broth
medium to give 2.4 ×107 cells ml-1 and SRE, SP22A or SP25A were added at designated
concentrations (between 0.81 and 9.33 uM). The suspensions were incubated with rotary
shaking at 28°C and samples removed hourly for direct cell counts. The number of cells
was counted using a hemocytometer and light microscope and generation times
determined from calculated specific growth rate constants.
K+ efflux
Whole cell K+ efflux rates were determined as changes in extracellular K+
concentrations. Yeast strain KZ1-1C was grown in YPD broth medium with rotary
shaking at 28oC to a density of 108 cells ml-1. Cells were suspended in 2 mM Tris/MES
buffer, pH6.5, and 0.1M-glucose with or without SRE, SP22A or SP25A (at
concentrations of 1, 10 or 100 µM) to A600 nm of 1 in 125 ml capacity Erlenmeyer flasks
with rotary shaking (200 rpm) at 28oC (Takemoto et al., 1991).

At 5 min after

suspension, 1 ml samples were withdrawn, centrifuged in an Eppendorf microcentrifuge
for 30 sec, and the supernatant fractions were recovered.

K+ concentrations were

determined by atomic absorption spectroscopy (AA/AE spectrophotometer 457,
Instrumentation Laboratories).
Ca2+ uptake
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The net cellular uptake of 45Ca2+ was measured using strain KZ1-1C as described
previously (Takemoto et al., 1991). Cells were grown in YPD broth medium to a density
of 1 X 107 cells ml-1, harvested by centrifugation, and then suspended in YPD broth
medium to a density of 4 x 107 cells ml-1). Ten mL aliquots were dispensed in 125 ml
capacity Erlenmeyer flasks with radioactive

45

CaCl2 (Amersham Radiochemicals) and

incubated with rotary shaking (200 rpm) at 28oC. The specific radioactivity of

45

Ca2+

was adjusted to 4mCi (148MBq) per mmole of CaCl2 (Takemoto et al., 1991). SRE,
SP22A or SP25A were added 5 min following addition of 45CaCl2. At designated times,
cell samples (200 µl) were collected on glass fiber filters (0.45 µM pore size), the filters
were quickly washed twice with ice-cold water, and the radioactivity on the filters
determined using a liquid scintillation counter.

Channel formation in lipid bilayers
Lipid bilayer electrophysiological experiments were performed using 1,2dioleoyl-sn-glycero-3-phosphorylcholine (DOPC) (Avanti Polar Lipids) as previously
described (Blasko et al., 1998; Malev et al., 2002). Solutions of 0.1 M NaCl were
buffered with 5 mM MOPS (Sigma) to pH 6. Bilayer lipid membranes were prepared by
the monolayer-opposition technique (Montal & Mueller, 1972) on a 50–100 µm diameter
aperture in the 10 µm thick Teflon film separating two (cis and trans) compartments of a
Teflon chamber. SP22A, SP25A, or SRE were added to the aqueous phase of the cis-side
compartment. A pair of Ag/AgCl electrodes with agarose/2 M KCl bridges was used to
apply transmembrane voltages and to measure single channel currents. All experiments
were performed at room temperature. Current measurements were carried out using an
Axopatch 200B amplifier (Axon Instruments) in the voltage clamp mode. The data were
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filtered with a low-pass 8-pole Model 9002 Bessel filter (Frequency Devices) at 1 kHz
and directly recorded into computer memory with a sampling frequency of 5 kHz. Data
were analyzed using pClamp 9.2 (Axon Instruments) and Origin 7.0 (Origin Lab).
Current transition histograms were generated for each tested voltage. Histogram peaks
were fitted with the normal distribution function. Single channel conductance was
calculated as the mean single-channel current divided by the applied transmembrane
voltage.

Results

Yeast growth inhibition by SP22A and SP25A
The growth of S. cerevisiae strain KZ1-1C in batch cultures with YPD broth
medium was completely inhibited by SP22A and SP25A at concentrations of 4.66 µM
and 8.24 µM, respectively (Table 5. 1). In contrast, SRE gave complete inhibition at
0.81 µM. In all cases, growth did not resume after 48h indicating that inhibition was
fungicidal.

Susceptibility of SRE-resistant lipid mutants
On replica-plated YPD agar medium SP22A and SP25A inhibited the growth of
parental yeast strains (W303C, BY4741, and 8A-1B) at 1.16 µM and 2.06 µM,
respectively (Fig. 5.1). Corresponding SRE-resistant isogenic mutant strains with
deletions in genes for sphingolipid (∆syr2, ∆ipt1, ∆elo2 and ∆elo3) or ergosterol (∆erg3)
biosynthesis were less susceptible to inhibition by SP22A and SP25A at these respective
concentrations (Fig. 5. 1). In contrast, sphingolipid α−hydroxylase mutant ∆fah1 was
more susceptible to SP22A than to SRE or SP25A. This mutant strain was nevertheless
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resistant to SP22A concentrations below 1 µM that were still inhibitory to isogenic strain
BY4741 (data not shown). Overall, the patterns of relative susceptibility and resistance
of the lipid mutants to SP22A and SP25A were similar to those shown previously for
SRE (Cliften et al., 1996; Hama et al., 2000; Stock et al., 2000).
Effects on K+ efflux
As previously observed for SRE (Takemoto et al., 1991), SP22A and SP25A
stimulated K+ efflux from cells of strain KZ1-1C (Fig. 5.2). Higher concentrations of
SP22A and SP25A were required to give the effect as compared to SRE.

SRE

stimulated K+ efflux as low as 1 µM. But, 10 and 100 µM of SP22A and SP25A,
respectively, were required to achieve similar degrees of K+ efflux.
Effects on Ca2+ uptake
As previously observed for SRE (Takemoto et al., 1991), SP22A and SP25A
stimulated Ca2+ uptake by strain KZ1-1C cells (Fig. 5. 3). As with K+ efflux (Fig. 5. 2),
higher concentrations of SP22A and SP25A, as compared to SRE, were required to
produce the effect. Ca2+ uptake was observed within 15 min after 5 µM SRE addition.
But, 40 µM and 120 µΜ were the minimal concentrations of SP22A and SP25A,
respectively, required for observing Ca2+ uptake. At these concentrations, Ca2+ uptake
was not evident until about 20 min and 30 min after addition of SP22A and SP25A,
respectively.

111
Channel formation in lipid bilayers
To examine the membrane channels properties of SRE and SPs, their effects on
ion conductance across planar lipid bilayers were measured. Figure.5. 4-A shows time
courses of the integral conductance of the bilayers doped with SP22A, SP25A, and SRE.
In all three cases, negative potential application drove the increase of the membrane
conductance after 5 min delay followed by stable conductance levels for 10 minutes.
Positive voltages produced membrane conductance decreases (not shown), indicating
closing of the pores. SP22A produced slightly higher conductance than SP25A (10
individual observations). SRE produced smaller steady-state conductance levels, even at
concentrations of SRE that were higher than those of the SPs (17 µM of SRE vs. 0.1 µM
of SP22A and 0.11 µM of SP25A).
The single-channel recordings with all three lipodepsipeptides were similar (Fig.
5.4). In all cases, two types of single-channel conductance fluctuations were observed,
small and large, differing in the levels of conductance 5 to 6 fold. The dwell times of the
large channels were longer than the small ones. The values of the single-channel
conductance for the small channels over the range of ±200 mV were similar for all three
lipodepsipeptides (Fig. 5.4-C). Thus, the properties of the transmembrane channels,
formed by SRE, SP22A, and SP25A were essentially the same.

Discussion

Despite the structural differences between SRE, SP22A, and SP25A, all three
lipodepsipeptides displayed similar physiological and model membrane-permeabilyzing
activities. They stimulated Ca2+ uptake and K+ efflux by yeast cells. SRE, however, was
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active at lower concentrations compared to the SPs, which parallels its relatively higher
fungicidal activities. As in the case of SRE, it is not yet known how the SPs cause
changes in fluxes.

However, it is likely that they both form pores in the plasma

membrane as a key step in their action that leads to ion leakage, membrane dysfunction,
and possibly other cell-damaging effects. It is also shown that growth inhibition by the
SPs is modulated by sphingolipids and sterols, which also is the case with inhibition by
SRE (Cliften et al., 1996; Hama et al., 2000). Sphingolipids and sterol biosynthetic
mutants of yeast were less susceptible to SP22A and SP25A as compared to the isogenic
wild type strains. By analogy to SRE action, it is suggested that the SPs also impart
fungicidal activities by forming lipidic pores that are influenced by specific sphingolipids
and sterols (Malev et al., 2002; Takemoto, 2003; Kaulin et al., 2005).
To further explore their resemblance, the transmembrane channel properties of
SP22A and SP25A were examined and compared to those of SRE channels. SP22A and
SP25A caused voltage-dependent macroscopic conductance increase due to the formation
of ion-permeable channels in the membrane bilayers. Both SPs were ~150 times more
effective in channel formation than SRE. At the same time, despite large structural
differences, the properties of single channel formed by all three cyclic lipodepsipeptides
were very close (Fig. 4.5).

Thus, the differences in macroscopic transmembrane

conductance levels were mostly due to differences in the total numbers of channels
formed by SRE vs. SP22A and SP25A. We suggest that the observed differences in the
membrane activity of SPs and SRE most likely stem from the structural differences in
their molecules, and, subsequently, from differences in interaction with the DOPC
bilayers. As opposed to the SPs, SRE lacks a hydrophobic peptide domain. SP22 and
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SP25 have hydrophobic peptide domains of fourteen and seventeen amino acids,
respectively (Ballio et al., 1991). As a consequence, the SPs will interact more favorably
with the lipid bilayer than will SRE. It is not known precisely how the SPs and SRE
interact with membrane lipids to form channels (Malev et al., 2002). However, the
electrostatic and hydrophobic interactions between SP22A and the lipid membrane are
known to increase lipid order as a prelude to stable pore formation (Szabo et al., 2004).
In addition, it was shown that unlike SRE, the SP22A pore was not thermally inactivated
suggesting a higher degree of affinity between SP22A and membrane lipids.
In summary, the present study suggests that although different in fungicidal
potencies, SRE and the two SPs kill yeast cells by the same mechanism, involving lipiddependent membrane pore formation as a crucial step. Like SRE, the action of the SPs
against yeast is promoted by sphingolipids and sterols of the plasma membrane. Our
observations also show that the structures of pores formed by SRE and the SPs in
membranes are very similar despite large structural differences between these molecules.
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TABLE. 5.1. Effects of SRE, SP22A, and SP25A on batch culture growth of S.
cerevisiae strain KZ-IC*
Additions to

+

Generation time (hr)

medium (µM)

None

5.33

SRE
0.81

∞

2.33

8.66

4.66

∞

9.33

∞

2.06

6.3

4.12

8.66

8.24

∞

SP22A

SP25A

* Growth was determined by microscopic direct cell counts during exponential growth in
YPD broth medium.
+
Calculated as 0.693 divided by the specific growth rate (cell doubling hr-1) during
exponential growth.
∞ = infinite
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FIG. 5.1. Effect of SRE and SPs on growth of yeast lipid biosynthetic mutants.
Sphingolipid and ergosterol biosynthesis mutant and parental strains were replica plated
onto YPD agar with or without: SP25A (2.06µM), SP22A (1.16µM), or SRE (0.61µM).
The plates were incubated at 28°C for 48 h.
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FIG. 5.2. Effects of SRE (blank bars), SP22A (grey bars) and SP25A (striped bars) on
K+ efflux by yeast strain KZ1-1C cells growing in YPD medium. The cells were
exposed to designated concentrations of SRE, SP22A or SP25A and extracellular K+
concentrations measured . The same results were obtained from three separate
experiments. Results from a single experiment are presented. Control efflux was
similar to SP25A at 1µM.
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FIG. 5.3. Effects of SRE, SP22A and SP25A on 45Ca2+ uptake by strain KZ1-1C
cell suspensions. SRE and SPs were added 5 min following addition of 45CaCl2.
SP22A concentrations were 10 (♦). 40 (■); SP25A (dashed lines) concentrations
were 10 (♦) , 40 (○) , and 120 (∆) µM; SRE concentration was 5µM (•). Total CaCl2
concentration was 50 µM. The same results were obtained from two separate
experiments. Results from a single experiment are presented.
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FIG. 5.4. (A) Time courses of the ion conductance of the bilayers doped with SRE, SP22A,
and SP25A, recorded at the applied voltage of –100 mV. (B) Records of conductance
fluctuations at –150 mV transmembrane potential of SRE, SP22A, and SP25A-modifuied
bilayers. (C) conductance-voltage curves for SRE, SP22A and SP25A small channels
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CHAPTER 6
SYRINGOPEPTIN SP25A INHIBITION OF GRAM-POSITIVE
BACTERIA AND ROLE OF TEICHOIC ACID
D-ALANYLATION

Introduction

The syringopeptins are secondary metabolites produced by many strains of the
plant-associated bacterium Pseudomonas syringae (Ballio et al., 1991; Bender et al.,
1999). They are cyclic lipodepsipeptides, with their peptide portions containing either 22
[syringopeptins (SP)22] or 25 (SP25) amino acids that are predominantly hydrophobic
and largely of the d configuration (Ballio et al., 1991; Isogai et al., 1995) (Fig. 6.1). A
common N-terminus dehydroaminobutyric acid (Dhb) is amide linked to a 3hydroxylated acyl chain containing 10 or 12 carbons to give A and B homologs,
respectively. The C-terminus carboxyl group is ester linked to a Thr hydroxyl to form an
eight-membered amino acid lactone ring with a net cationic charge. SP25 homologs,
SP25A and SP25B, are produced by strains of P. syringae pv. syringae isolated from
millet (strain B359; Ballio et al., 1991), citrus (strain B427; Ballio et al., 1991), and
wheat (strain M1; Adetuyi et al., 1995), and by the wheat pathogen P. syringae pv.
atrofaciens (Vassilev et al., 1996). Variants differing in the C-terminal residue (Phe vs.
Tyr) are produced by a laurel-infecting P. syringae strain (Scaloni et al., 1997). SP22 A
and B homologs are produced by the pear isolate P. syringae pv. syringae strain B301
(Ballio et al., 1991), and variants are produced by P. syringae pv. syringae isolates from
sugar cane [SP(SC; Isogai et al., 1995)], bean (SPPhv; Grgurina et al., 2002), and apple
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(SP508; Grgurina et al., 2005). All syringopeptin-producing P. syringae strains produce
one type of syringopeptin together with a smaller, nine amino acid-containing cyclic
lipodepsipeptide – either syringomycin, syringotoxin, syringostatin, or pseudomycin
(Bender et al., 1999; Takemoto et al., 2003). The syringopeptins are phytotoxic and also
antimicrobial. In plant systems, they perturb mitochondria and protoplasts of tobacco
leaves (Iacobellis et al., 1992; Hutchison & Gross, 1997) and form ion channels in sugar
beet vacuoles (Carpaneto et al., 2002). They are also antifungal (Iacobellis et al., 1992;
Lavermicocca et al., 1997), particularly when combined with cell wall-degrading
enzymes (Fogliano et al., 2002). SP22A and SP508A have antibacterial activities against
several Gram-positive bacteria such as Bacillus megaterium, Staphylococcus aureus, and
Mycobacterium smegmatis but not against Gram-negative bacteria (Lavermicocca et al.,
1997; Grgurina et al., 2005). In contrast, the antibacterial spectrum for SP25A is less well
known, although it is reported to inhibit B. megaterium and to inhibit Micrococcus luteus
marginally (Lavermicocca et al., 1997). The molecular basis for the inhibitory specificity
of syringopeptins against Gram-positive bacteria is not known. The most probable
physiological targets of the syringopeptins are membranes, and lipid bilayer studies
suggest that the inhibitory mechanism of action involves formation of membrane pores
(Hutchison & Gross, 1997; Dalla Serra et al., 1999).
Teichoic acids are major cell surface components of Gram-positive bacteria that
confer high densities of negative charges (phosphate groups) on the cell envelope surface.
Such anionic sites might serve as initial ionic interaction sites for the cationic 'head
groups' of the syringopeptins. The charge densities of peptidoglycan-linked wall teichoic
acids and membrane-linked lipoteichoic acids are modulated by esterification with d-
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alanine. The enzymes that catalyze and regulate teichoic acid d-alanylation are encoded
by five genes of the dlt operon (Perego et al., 1995). Genes dltA and dltC encode a dalanine-d-alanyl carrier protein ligase and d-alanyl carrier protein, respectively. Both dltB
and dltD encoded proteins facilitate the transport of activated d-alanine across the
membrane for incorporation into lipoteichoic acid. The function of the fifth gene of the B.
subtilis dlt operon, dltE, remains unknown and defects in dltE do not lead to impairment
of d-alanylation. d-alanine moieties of lipoteichoic acid serve as precursors for dalanylation of wall-linked teichoic acids (Haas et al., 1984). Studies with dlt mutants
reveal that teichoic acid d-alanylation is not essential for viability (Perego et al., 1995),
but the process influences susceptibility to lysis (Peschel et al., 1999), acid (Boyd et al.,
2000), and antimicrobial peptides (Peschel et al., 2000; Kristian et al., 2005).
In the present study, the antimicrobial spectrum of SP25A and it is shown that it
specifically inhibits Gram-positive bacteria is explored further. This includes B.
megaterium, which was previously shown to be sensitive to this syringopeptin (Iacobellis
et al., 1992; Lavermicocca et al., 1997). Data are reported that reveal a role for dalanylation of teichoic acids in modulating the susceptibility of B. subtilis to SP25A and
other syringopeptins. This is consistent with the cationic character of the cyclic peptide
portion of SP25A, and it provides an explanation for its higher degree of specificity for
Gram-positive bacteria.
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Materials and Methods

Syringopeptin purification
SP25A, SP22A, and SP508A were purified from cultures of P. syringae pv.
syringae strains M1 (Adetuyi et al., 1995), B301D (DeVay et al., 1968) and 508
(Grgurina et al., 2005), respectively, following previously described methods (Ballio et
al., 1991). Cultures were extracted with acidified acetone (0.4% HCl), and extracts were
chromatographed on Amberlite XAD-2 (Bidwai et al., 1987). Final purification was
achieved by preparative HPLC using a Varian 5000 system and an Alltech reverse-phase
C18 silica column (Bidwai et al., 1987). For growth inhibition studies, dry and purified
syringopeptins were each gravimetrically weighed, mixed in 0.001N HCl at a
concentration of 10 mg mL−1 (4.6, 4.5, and 4.1 mM for SP22A, SP508A, and SP25A,
respectively), and diluted accordingly with distilled water before use.

Organisms and culture conditions
The following organisms were obtained from the American Type Culture
Collection (Manassas, VA): M. smegmatis ATCC 14468, Staphylococcus aureus ATCC
6538, B. megaterium ATCC 14381, B. subtilis ATCC 1965, Alcaligenes faecalis ATCC
8750, Escherichia coli ATCC 25922, Proteus vulgaris ATCC 13315, Pseudomonas
aeruginosa ATCC 15442, Salmonella enterica (serovar typhimurium) ATCC 14028,
Serratia marcescens ATCC 8100, and Citrobacter freundii ATCC 8090.

Listeria

monocytogenes ATCC 82302and a laboratory strain of Listeria innocua were obtained
from B. Weimer (Department of Nutrition and Food Sciences, Utah State University).
Streptococcus agalactiae and Streptococcus pyogenes strains were obtained from the
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Department of Biology Culture Collection, Utah State University. Mycobacterium
smegmatis was grown at 37°C in Middlebrook 7H9 broth supplemented with 0.2%
glycerol and 10% Middlebrook oleic acid-albumin-dextrose-catalase enrichment.
Staphylococcus aureus was grown at 37°C in Mueller–Hinton medium (Difco), and B.
megaterium and B. subtilis were grown in Luria–Bertani (LB) medium (Sambrook et al.,
1989) at 37°C. Listeria monocytogenes, and L. innocua were grown on brain heart
infusion medium (Difco) at 37°C. Alcaligenes faecalis, E. coli, Proteus vulgaris,
Pseudomonas

aeruginosa,

Salmonella

enterica

serovar

typhimurium,

Serratia

marcescens, and C. freundii were grown on LB medium at 37°C. Streptococcus
agalactiae and Streptococcus pyogenes were cultured on blood agar medium as described
by Jasir et al. (2003). Bacillus subtilis teichoic acid d-alanylation mutant strains and
wild-type JH642 (trpC2, phe-1) (Perego et al., 1995) were obtained from Z. Pragai
(University of Newcastle Upon Tyne). The mutant strains were deleted in dltB and dltD
by insertional mutagenesis with integrative vectors pDLT72 (derived from pJM103) and
pDLT74A (derived from JM105A), respectively. Both mutants are deficient in d-alanine
esterification of lipoteichoic acids and wall teichoic acids (Perego et al., 1995). A third
dlt operon mutant strain disrupted by pDLT76 (derived from pDLT74A) and with a
truncated dltD gene and completely defective dltE still incorporates d-alanine into
lipoteichoic acid and wall teichoic acids at wild-type levels (Perego et al., 1995). Wildtype strain JH642 was grown in LB medium, and the dlt mutant strains were grown in LB
medium in the presence of 5 µg mL−1 chloramphenicol, 2 µg mL−1 kanamaycin, and
1 µg mL−1 erythromycin (Perego et al., 1995).
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Effects of SP25A on batch culture
growth of B. subtilis
Bacillus subtilis strains ATCC 1965, JH642 (trpC2, phe-1), pDLT72, and
pDLT74A were each initially grown in 25 mL nutrient broth in 125 mL capacity
Erlenmeyer flasks with gyratory shaking (200 r.p.m.) in a New Brunswick G26 incubator
shaker for 24 h at 37°C. Ten microlitres of each of the cultures were transferred into
100 mL of fresh nutrient broth medium in 250 mL capacity Erlenmeyer flasks containing
0 (control), 5, or 10 µg mL−1 of SP25A. The flasks were incubated at 37°C with gyratory
shaking in a New Brunswick G76 water bath incubator (speed setting at 6). Cell
turbidities at designated times were measured at an absorbance wavelength of 660 nm
with a Shimadzu UV1201 spectrophotometer using 1 cm path length cuvettes.

Determination of minimal inhibitory
concentration (MIC) values
The Clinical and Laboratory Standards Institute (CLSI; formerly NCCLS)approved standard reference methods for microbroth dilution susceptibility assays were
performed to obtain MIC values (NCCLS, 1993, 2003). Bacteria, except for M.
smegmatis and Streptococcus agalactiae and Streptococcus pyogenes, were grown to a
final concentration of 108 CFU mL−1 and suspended to a final concentration of 5 ×
105 CFU mL−1. Cell suspensions (25–50 µL) and 10 µL aliquots of twofold dilutions of
SP25A were deposited in wells of 96-well polystyrene plates. The plates were incubated
at 37°C for 16–20 h. Mycobacterium smegmatis cells were grown to a density of 1.0
McFarland unit (c. 3 × 108 CFU mL−1; Liu & Nikaido, 1999), and Streptococcus
agalactiae and Streptococcus pyogenes colonies grown on blood agar plates were
suspended to 0.5 McFarland units (c. 1.5 × 108 CFU mL−1) in saline (Jasir et al., 2003).
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Inocula were diluted to 5 × 104 CFU mL−1, the cells were dispensed, and twofold dilution
series of SP25A (initial concentration 1.0 mg mL−1) were applied to 96-well polystyrene
plates. MICs were determined after 48-h incubation at 37°C. Minimum bacteriocidal
concentrations were determined as described by Perry et al. (1999). After MIC
determinations, 100 µL aliquots were removed from each micrototiter plate well and
spread-plated on appropriate agar medium. All plates were incubated at the optimal
temperature for each organism and growing colonies were counted after 24–48 h. The
minimal bacteriocidal concentration values were determined as the lowest concentrations
of SP25A that yielded a >99.9% killing of the organism. Half-maximal inhibitory
concentration (IC50) values were determined as the SP25A concentration yielding 50%
killing.

Determination of disk diffusion zone
of inhibition (ZI) diameters
Disk diffusion assays were performed according to CLSI-approved standard
reference methods (NCCLS, 1993) with modification. Bacteria were grown in
appropriate media for 24–48 h. The culture densities were adjusted to 0.5 McFarland
units, and cultures were spread on agar plate medium surfaces. Sterilized paper disks
(0.5 cm diameter) were placed on the inoculated agar medium surfaces. Ten microlitres
aliquots of SP25A solutions were applied to the disks , and the plates were incubated for
16–24 h at optimal temperature (37 or 28°C) before examination and measurement of the
diameters of the cleared ZIs. To examine pH effects on syringopeptin activities using disk
diffusion assays, B. subtilis strains JH642 (trpC2, phe-1), dltB, dltD, and dltE mutant
strains were spread-plated onto surfaces of LB agar medium adjusted to pHs 7.0, 9.0, or
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5.8, syringopeptins SP25A, SP22A, or SP508A applied to disks as described above, and
the LB agar medium plates incubated at 37°C for 16–24 h.

Results and Discussion

Inhibition of bacteria by SP25A
Previous studies by Lavermicocca et al. (1997) showed that SP25A inhibited the
growth of B. megaterium but not of several Gram-negative bacteria. In the present study,
the inhibitory effects of SP25A against additional Gram-positive bacteria were examined,
and its effects against Gram-negative bacteria were re-evaluated (Table. 6.1). MICs
ranged between 1.95 and 7.8 µg mL−1 for all Gram-positive bacteria tested. The
inhibition by SP25A was bacteriocidal as the minimal bacteriocidal concentrations were
identical to the MICs. IC50 values were twofold lower than the corresponding MIC
values. In contrast and consistent with the previous observations (Lavermicocca et al.,
1997), none of the Gram-negative bacterial species tested were inhibited by SP25A
(Table. 6.1).

Effects of SP25A on B. subtilis teichoic
acid d-alanylation mutants
The basis for SP25A's specificity against Gram-positive bacteria was studied
using B. subtilis teichoic acid d-alanylation dlt mutants. SP25A at 5 µg mL−1 inhibited dlt
operon wild-type B. subtilis strains JH642 (trpC2, phe-1) to varying degrees when grown
with aeration at 37°C in nutrient broth (Fig.6.2). Strain JH642 grew slowly with
5 µg mL−1 SP25A with a generation time of 6.97±0.07 h compared with a generation time
of 1.58±0.41 h when grown with no added SP25A. In contrast, d-alanylation mutant
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strains pDLT74A (dltB deletion) and pDLT72 (dltD deletion) (both constructed in strain
JH642) were completely inhibited by 5 µg mL−1 SP25A. Therefore, the lack of dalanylation of teichoic acids led to a higher degree of sensitivity to SP25A. SP25A at
10 µg mL−1 completely inhibited the growth of these strains as well as B. subtilis strain
ATCC 1965. The higher sensitivities of the dltB and dltD mutants were also evident from
microbroth dilution susceptibility and disk diffusion assays. Both mutants showed
approximately fourfold lesser MIC values (0.98 µg mL−1) and twofold larger ZI
diameters (19–20 mm) compared with the parent wild-type strain JH642 (3.95 µg mL−1
and 10 mm, respectively) (Table.6.1). With both assays, the mutant strain inactivated in
dltE served as an integrative vector control, and it showed susceptibilities comparable to
the parental strain JH642 (Table. 6.1).Effect of pH on SP25A inhibiton of B. subtilis
strains and comparisons with SP22A and SP508A. Alkaline pH promotes the hydrolytic
removal of d-alanine from teichoic acids (MacArthur & Archibald, 1984; Hyyrylainen et
al., 2000). As d-alanylation has the effect of masking the phosphate-negative charges of
teichoic acids, it was speculated that alkaline pHs will increase the potential for
interaction and therefore susceptibility of B. subtilis to cationic SP25A. Such an effect
was observed. In disk diffusion assays (Table.6.2), SP25A gave larger ZI diameters (30–
50%) with B. subtilis wild-type strain JH642 at pH 9.0 as compared with pH 7.0 and 5.8.
In contrast, the ZI diameters with the dltB and dltD mutants were comparable or slightly
larger (10–15%) at pH 9.0 as compared with pH 7.0 and 5.8 (Table. 6.2). The integrative
vector control dltE mutant displayed the same degrees of inhibition as parental strain
JH642 at all three pHs. The alkaline pH effect was also analyzed with syringopeptins,
SP22A and SP508A. With these syringopeptins, the ZI diameters were essentially the
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same at pHs 7.0 and 9.0 with all strains tested (parental wild type and dltB and dltD
mutants; Table 2). However, SP22A displayed higher degrees of growth inhibition of the
dltB and dltD mutants at acidic pH. At pH 5.8, the ZI diameters were 30–40% larger for
both mutants as compared with the cases at pH 7.0 and 9.0. Although uncertain, it is
conceivable that the chemical stabilities of SP22A and SP508A were compromised at pH
9.0. These findings expand upon previous reports concerning SP25A's inhibitory activity
against B. megaterium (Iacobellis et al., 1992; Lavermicocca et al., 1997), and they
solidify the notion that the antibacterial spectrum of the syringopeptins is confined to
Gram-positive bacteria (Grgurina et al., 2002, 2005). The variability in MICs (ranging
from 1.95 to 7.8 µg mL−1) among the Gram-positive species is likely due to the evolving
variations in cell surface structure and charge distribution that occur with these organisms
(Peschel & Sahl, 2006). Like SP22A and SP508A (Grgurina et al., 2005), SP25A is
inhibitory to M. smegmatis, raising the prospect that these lipopeptides may be developed
as antimycobacterial therapeutics.
This study shows that the anionic charges of teichoic acids are important for
SP25A's inhibitory action against B. subtilis. In contrast, SP22A and SP508A are less
reliant on teichoic acid charge as the dlt mutant strains were as susceptible as the parental
wild-type strain to these syringopeptins. Two principal structural differences between
SP25A vs. SP22A and SP508A may account for this disparity: (1) SP25A possesses
valine instead of dehydroaminobutyrate at the fourth position of the cyclic portion of the
peptide (from the N-terminus), and (2) SP25A has an additional three amino acids in the
hydrophobic portion of the peptide. It is speculated that one or both of these features
promotes interaction between the cationic charges of the SP25A cyclic peptide moiety
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and the anionic teichoic acid phosphate groups and that such interactions are weaker or
lacking with SP22A and SP508A. Differences in the modes of interactions of these
syringopeptins with the cell surface were also evident by the increased level of inhibition
by SP22A and SP508A at acidic pH, but not by SP25A. The acidic effect seen with the
former two syringopeptins remains unexplained as well as a mechanism to account for
their specific growth inhibition of Gram-positive bacteria. Of relevance is the observation
that growth inhibition by positively charged polylysine is not altered in dlt mutants of
Staphylococcus species (Peschel et al., 1999). Apparently, cationic properties alone are
not sufficient for peptides to inhibit selectively the growth of Gram-positive bacteria even
when lacking teichoic acid d-alanines.
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Table 6.1. SP25A inhibitory activities against bacterial
species and strains.
1

M. smegmatis ATCC14468

MIC
(µg/ml)
1.95

ZI
diameter(mm)
25

S. aureus ATCC6538

1.95

17

B. megaterium ATCC14381

1.95

13

B. subtilis ATCC1965

3.9

11

L. monocytogenes ATCC82302

3.9

ND

L. innocua

3.9

ND

B. subtilis JH642

3.9

10

Organism

B. subtilis dltB mutant strain (Perego, 0.98

2

19

et al., 1995)
B. subtilis dltD mutant strain (Perego, 0.98

20

et al., 1995)
B. subtilis dltE mutant strain (Perego, 3.9

11

et al., 1995)
A. faecalis ATCC8750

>250

<1

E. coli ATCC25922

>250

<1

P. vulgaris ATCC13315

>250

<1

P. aeruginosa ATCC15442

>250

<1

S. typhimurium ATCC14028

>250

<1

S. marcescens ATCC8100

>250

<1

C. freundii ATCC8090

>250

<1

1

MIC values represent two or three matching values from three experiments .
The initial undiluted SP25A concentration was 5 mg per ml.
2
Error was +/- 2 mm from duplicate determinations.
ND= not determined
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Table 6. 2. Inhibition of Bacillus subtilis strains by SP25A, SP22A
and SP508A at pH 7.0, 5.8, and 9.0
Strain

*

ZI diameter (mm)

SP25A

SP22A

SP508A

7.0

5.8

9.0

7.0

5.8

9.0

7.0

5.8

9.0

JH642†

10

13

15

9

9

10

9

8

10

dltB mutant‡

19

19

22

10

13

9

8

11

7

dltD mutant‡

20

18

22

9

13

10

8

11

10

dltE mutant†

11

13

14

8

9

8

9

9

8
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Fig. 6.1. Structures of SP25A, SP22A, and SP508A. R is 3-hydroxydodecanoyl in
SP508A and 3-hydroxydecanoyl in SP22A and SP25A
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Fig. 6.2. Inhibitory effects of SP25A (5 µg mL−1) on the growth of Bacillus subtilis
strains JH642 (•), dltB mutant (○), and dltD mutant (▪) strains and the growth of
B. subtilis JH642 in the absence of SP25A (▴). A660 nm is optical absorbance at 660 nm.
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CHAPTER 7
SUMMARY AND FUTURE DIRECTIONS

The need for new antifungals and fungicidal biocontrol agents is growing due to
the narrowing spectrum of fungal targets and increasing resistance to existing antifungals
such as amphotericin B and the azoles (11, 12).

One approach to develop novel

antifungals is to combine known antifungal compounds.
The focus of this research was to examine the bioactive properties of SRE and
RLZonix against bacteria, yeast, and filamentous fungi. Previous studies have shown that
SRE has inhibitory activity against yeast and fungi ( MICs range, 6.25-40 µg/ml)
(13, 7, 15) . However, no activity against bacteria was reported. Moreover, Haba et al.
(1, 6) have shown that RLs have antibacterial activities against certain fungi, Gramnegative and Gram-positive bacteria. Although no activity against yeast was observed.
In this study I report strong synergistic antifungal activities between SRE and RLZonix in
the mixtures (SYRAs).

The SRE minimal inhibitory concentrations (MICs) were

lowered when combined with RLZonix.

However, no activity was observed against

bacteria.
In vitro cytotoxicity and erythrocyte lysis were also investigated. The hemolytic
activity and cytotoxicity of SYRA was dose dependent. However, the concentrations of
SRE in SYRA that caused hemolysis and cytotoxicity were 3 to 5 times higher than the
MICs. In addition, the honeybee toxicity effect of SYRA was also studied. The results
showed no toxicity at concentrations higher than the MICs. The synergistic antifungal
interaction between SRE and RL occurred at low concentrations of SRE. As a result, the
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effective antifungal concentration of SYRA was not toxic. These results present new
findings and potential uses for alternative therapeutics against pathogenic yeasts and
fungi in various applications such as agriculture and medicine.
To further explore their candidacies as agrofungicides, SRE and SYRA
formulations were exposed to different temperatures and pHs, and subjected to
autoclaving, ultraviolet light, sonication, and proteolysis. The treated solutions were
tested for antifungal activities and analyzed by RP-HPLC in the cases of temperature and
proteolysis treatments. In addition, SRE and SYRA were mixed with mineral oil and
their activities were tested. The overall results showed significantly high stabilities of
SRE and SYRA under the tested conditions. The data indicate a possible exploitation of
SYRA as agrofungicide.
Finally, I studied the mechanism of action of SYRA using Saccharomyces
cerevisiae strains deficient in various steps of sphingolipid and sterol biosynthesis as a
model.

I also studied the channel-forming properties of SYRA in lipid bilayers in

comparison with those of SRE. Previously, it was shown that SRE acts on yeast and
plant plasma membranes to cause numerous cellular effects with increases in cellular K+
efflux and transient Ca2+ fluxes among the most prominent. The effects are consistent
with SRE’s ability to form ion-conducting voltage sensitive channels in membrane
bilayers. In addition, studies with yeast have revealed that sphingolipids and sterols
(lipids that occur predominantly in the plasma membrane) modulate the fungicidal
activity of SRE (4, 5, 14). SRE lipidic pore formation has been proposed as the
mechanistic basis for SRE action on membranes (10). In this study the results suggest
that SYRA inhibits yeast by the same mechanism as does SRE by itself. Its antifungal
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action is promoted by sphingolipids and sterols of the plasma membrane and involves
pore formation. In addition, the present data provide an explanation for the antifungal
synergy between SRE and RLZonix. The addition of RLZonix resulted in an increase in the
number of membrane channels formed by SRE. I suggest that the observed increase in
the number of channels is due most likely to the enhancement and favorable binding of
SRE in the presence of RLZonix. However, the nature of interaction between SRE, RLZonix,
and the plasma membrane is not clear. One possibility is that the penetration of RLZonix
into the plasma membrane attracts more SRE binding to the membrane to give an
increase in number of channels. It would be of interest to induce RL into the lipid
membrane and study the attraction, insertion and orientation of SRE in the lipid
membrane using NMR spectroscopy or circular dichroism (CD) spectroscopy (8, 3).
Another approach will be to look directly at the SRE’s pore structure in the presence and
absence of RL using mercury porosimetry analyses and circular dichroism (CD)
spectroscopy (8). It’s noteworthy to mention that the nature of the membrane plays an
important role in how RLZonix binds and inserts into the membrane (2). Perhaps studying
the characterization of a single channel in membrane bilayers using different ratios of
lipids and solid-state NMR spectroscopy will help to define the interaction of SRE and
RL with the plasma membrane and the effects of membrane composition on their
antimicrobial activity.
In conclusion, these studies show strong synergism between SRE and RLZonix
against fungi and yeast including phytopathogenic species. The antifungal spectrum, low
toxicity, chemical and physical stabilities suggests that SYRA is a potential candidate for
fungicidal agricultural applications and antifungal therapy in medicine.

However,
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additional studies such as in vivo examination of SRE and RL mixtures are needed to
evaluate the significance of the combination as a potential antifungal therapy or
agricultural fungicide. To illustrate SYRA candidacy as antifungal agent, SYRA can be
tested against aspergillosis and candidiasis in animal models.

Additionally, further

studies in pharmacokinetics and pharmacodynamics can be performed to develop
strategies dosing for an optimize treatment (9). Furthermore, to explore the possibility of
SYRA as a biocontrol agent against phytopathogenic fungi, infected plants or infected
seeds can be used as a model. In addition, SYRA can also be tested as a postharvest
control agent by studying the effect of SYRA on infected and wounded fruit.
The studies reported here offer a new approach for developing new antifungal
agents. For example, combining rhamnolipids with other lipodepsipeptides such as
syringotoxins, syringostatins, and syringopeptins and with other amphipathic compounds
may lead to discoveries of novel and effective fungicidal formulations for future
applications in agriculture and medicine.
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APPENDIX A

ANTIMICROBIAL ACTIVITY OF SP25A- RLZonix AND GRAMICIDIN- RLZonix
COMBINATIONS

Disk diffusion tests were done according to NCCLS methods with modification
{Washington, 1995 #55}. Tested organisms were grown in appropriate media (Bacteria
strains were grown on Luria-Bertani medium except S. aureus was grown on MuellerHinton medium and R. pilimanae on potato dextrose broth ( PDB) for 24 to 48 h, and the
cell densities were adjusted to 0.5 McFarland standard. A 100 µl aliquot of each culture
was spread over the surface of the appropriate agar growth medium as a thin film. A 6
mm diameter sterilized paper disk was placed and pressed down onto the agar {Perego,
1995 #31}. The SP25A- RLZonix, and gramicidin-RLZonix combinations were prepared by
adding SP25A or gramicidin (both at 1 mg/ml) together with RLZonix (1 mg/ml) in ratios
of 1:3 [wt/wt] ,1:2 [wt/wt] and 3:1 [wt/wt], respectively. Ten µl of the mixtures were
applied onto the disks. The plates were incubated for 24 to 48 h and the zones of
inhibition were measured.
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Table. Antimicrobial activities of SP25A (1mg/ml)- RLZonix (1mg/ml) combinations.
Zone of inhibition (mm)
SP25A

RLZonix SP25A-RLZonix

SP25A-RLZonix

SP25A-RLZonix

1:2

1:3

3:1

R. pilimanae

10

>1

>1

>1

9

S. aureus

20

>1

9

>1

15

B. subtilis

12

>1

8

>1

9

E. coli

>1

>1

>1

>1

>1

Table. Antimicrobial activities of gramicidin (1mg/ml)-RLZonix (1mg/ml) combinations.
Zone of inhibition (mm)
Gramicidin

RLZonix

Gramicidin-

Gramicidin-

Gramicdin-

RLZonix

RLZonix

RLZonix

1:2

1:3

3:1

R. pilimanae

>1

>1

>1

>1

>1

S. aureus

25

>1

15

10

18

B. subtilis

23

>1

10

>1

15

E. coli

>1

>1

>1

>1

>1
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APPENDIX B

MECHANISM OF ACTION OF SP25A- RLzonix COMBINATION
To study the influence of RLZonix on SP25A interaction with the plasma
membrane, I examined the membrane channel forming properties of SP25A in the
presence and absence of RLZonix. The effects on ion conductance across planar lipid
bilayers were measured. The figure shows time courses of the integral macroscopic
conductance of the bilayers doped with SP25A alone and SP25A with RLZonix. The
results showed that the negative potential application drove the increase of the membrane
conductance. Remarkably, the addition of RLZonix to cis side of the bilayer caused no
changes in the membrane conductance.
Lipid bilayer electrophysiological experiments were performed using 1,2dioleoyl-sn-glycero-3-phosphorylcholine (DOPC), (Avanti Polar Lipids) as previously
described (Malev, et al., 2002) (Blasko, et al., 1998). Solutions of 0.1 M of NaCl were
buffered with 5 mM MOPS (Sigma) to pH 6. Bilayer lipid membranes were prepared by
the monolayer-opposition technique (Montal & Mueller, 1972) on a 50–100 µm diameter
aperture in the 10 µm thick Teflon film separating two (cis and trans) compartments of a
Teflon chamber (Bezrukov & Vodyanoy, 1993) (Montal & Mueller, 1972).

The

membrane-forming solution was DOPC. A pair of Ag/AgCl electrodes with agarose/2 M
KCl bridges was used to apply transmembrane voltages and to measure single channel
currents. Current measurements were carried out using an Axopatch 200B amplifier
(Axon Instruments) in the voltage clamp mode. The data were filtered with a low-pass 8pole Model 9002 Bessel filter (Frequency Devices) at 1 kHz and directly recorded into
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computer memory with a sampling frequency of 5 kHz. Data were analyzed using
pClamp 9.2 (Axon Instruments) and Origin 7.0 (Origin Lab).

Single channel

conductance was calculated as the mean single-channel current divided by the applied
transmembrane voltage. All experiments were performed at room temperature.
SP25A (1 µg/ml ) and RLZonix (4 µg/ml) were added to the aqueous phase as fellows :
5- At t=0, SP25A was added to cis side compartment
6- At t=0, RLZonix was added to cis side compartment, then at t=10 min, SP25A was
added to the same side.

Time courses of the ion conductance of the bilayers doped with A)- SP25A applied
to cis side. B)- SP25A and RLZonix applied to Cis side.
recorded at the applied voltage of –50 mV
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APPENDIX C

ANTIFUNGAL ACTIVITY OF PSEUDOMONAS SYRINGAE PV SYRINGAE
SYRINGOMYCIN EXTRACT AND RHAMNOLIPID
COMBINATIONS

Syringomycin extracts were purified from P.syringae pv.syringae strain M1 by
the method of Bidwai et.al {Bidwai, 1987 #242}. Five-hundred ml-capacity Erlenmeyer
flasks containing 250ml of PDB medium were inoculated with 1 ml of an actively
growing culture. The flasks were incubated at room temperature without shaking for 7 to
14 days. The flasks were chilled to 4°C and 250 ml of cold acidified acetone was added
(4 ml HCl per litter acetone). The debris and cells were removed by centrifugation. The
supernatant was then concentrated by rotary evaporation to 400 ml. Then, 600 ml of
acetone were added and the suspension was stirred overnight at 4°C. Finally, the
suspension was centrifuged and the supernatant was removed and concentrated, then
diluted to 1 l with 0.l% trifluoroacetic acid (TFA). The TFA solution was applied to an
Amberlite XAD-2 (20 to 50 mesh) column (3×25 cm). The crude extract was eluted with
0.1% TFA using a nonlinear gradient of 2-propanol. The 2-propanol was removed using
a rotary evaporator and the solution was concentrated and lyophilized. The sample was
dissolved in 15 ml of water:acetone (40:60 v/v). The final extract was diluted 2-1 to 2-4
with water before mixing (1:1 v/v) with 1 mg per ml rhamnolipid (Zonix or RLZonix) .
Commercial RLZonix) was obtained from Jeneil Biotech, Inc. RLZonix is an 8.5% (wt/vol)
solution of rhamnolipid analogs in water. Two forms of rhamnolipids are in RLZonix, R1
(C26H48O9) has the molecular formula of α-L-rhamnopyranosyl-β-hydroxydecanoyl-β-
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hydroxydecanoate,

and

R2(C32H58O13)

is

2-O-α-L-rhamnopyranosylα-L-

rhamnopyranosyl- β hydroxydecanoate.
The combinations were prepared by mixing RLZonix with diluted syringomycin
extract.
Method similar to those described by the NCCLS protocols for antifungal testing
{Washington, 1995 #55} was used. R. pilimanae was grown on PDB medium and
adjusted to 5×104 CFU per ml {Shin, 2003 #63} {Johnson, 1999 #65}. A 100µl of the
culture was transferred onto solid agar medium. The culture was spread over the surface
as a thin film {Shin, 2003 #63}. Four mm diameter sterilized paper disk was deposited on
the surface. Different mixtures of diluted crude extract and RLZonix were prepared and
applied on a disk (7 to 10 µl aliquots). The plate was incubated at 28°C for 24 h and the
zone of inhibition was measured {Cuenca-Estrella, 2003 #61}.
The antifungal activity of crude extract is shown in Table (Appendix C). The
crude extract and RLZonix showed strong antifungal synergism against R. pilimanae. The
zones of inhibition of the combinations were greater than the crude extract applied alone.
The strongest activity was observed when 3 mg/ml of RLZonix was combined with 1/16 of
the crude extract.
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Table (Appendix C). Antifungal activity of syringomycin extract and RLZonix
combinations against R. pilimanae.
Zone of inhibition (mm)
3
0.850

RLZonix
(1 mg/ml)

--

18.75

Dilution of syringomycin
extract
(1 mg per ml) in mixed with
RLZonix
(1 mg/ml)
1
½
¼
1/8
1/16

--

--

--

--

--

15
14
13
12
12

ND
ND
38
44
36

ND
ND
30
42
45

ND
ND
20
21
20

ND
ND
15
15
15

ND: not determined

0.250
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APPENDIX D

POSTHARVEST CONTROL OF FUNGI USING SRE AND SYRA

Postharvest fruit biocontrol assays were done by methods described by Bull et al.
{Bull, 1998 #151} and Zhou et al. {Ting Zhou, 2001 #261} with modification. Peaches
(variety E lberta) free of wounds and pesticide-free were obtained form a local home
garden (Jon Takemoto, North Logan, Utah). The fruits were washed using sterile water.
The fruits were wounded using a sterile steel rod and 20µl of spore (1× 108 spore/ml)
suspension was placed in the wound and allowed to dry. SRE ( 40 µg/ml) and SYRA
( SRE 40 µg/ml, RLZonix 120 µg/ml) were then applied. The fruits were kept at room
temperature and photographs recorded after 3 days. Each tray held three fruits and each
experiment was done three times.
The treatment with SRE and SYRA provided significant reduction in the growth
of tested fungi and it was effective in controlling Botrytis cinerea and Rhizopus stonifer
on peaches.
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A

B

C
Fig. Biocontrol assay. Botrytis cinerea (A), Rhizopus stonifer (B), Penicillium oxalicum
(C). 20µl of spore were dropped on the wound. The 20µl of SRE (40 µg/ml) and SYRA
( SRE 40 µg/ml, RLZonix 120 µg/ml ) were applied after the spore suspension was dried.

